US5679647A - Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides - Google Patents

Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides Download PDF

Info

Publication number
US5679647A
US5679647A US08/334,260 US33426094A US5679647A US 5679647 A US5679647 A US 5679647A US 33426094 A US33426094 A US 33426094A US 5679647 A US5679647 A US 5679647A
Authority
US
United States
Prior art keywords
antigen
tumor
host
cells
polynucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/334,260
Other languages
English (en)
Inventor
Dennis A. Carson
Eyal Raz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23306377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US5679647(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US1994/009661 external-priority patent/WO1995005853A1/fr
Priority to US08/334,260 priority Critical patent/US5679647A/en
Application filed by University of California filed Critical University of California
Assigned to REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE reassignment REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CARSON, DENNIS A., RAZ, EYAL
Priority to AT95940581T priority patent/ATE323496T1/de
Priority to EP95940581A priority patent/EP0789574B1/fr
Priority to AU41981/96A priority patent/AU4198196A/en
Priority to DE69534946T priority patent/DE69534946T2/de
Priority to JP8515385A priority patent/JPH10509702A/ja
Priority to CA002203991A priority patent/CA2203991C/fr
Priority to PCT/US1995/014097 priority patent/WO1996014074A1/fr
Publication of US5679647A publication Critical patent/US5679647A/en
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
    • A61B17/205—Vaccinating by means of needles or other puncturing devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • This invention relates to methods for administering biologically active peptides to a mammalian host by the introduction thereto of one or more polynucleotides to operatively encode for the peptides, preferably by non-invasive means. It also relates to the administration of said polynucleotides to immunize a host against one or more antigens. In particular, the invention relates to the immunization of a host against one or more organ-specific, tumor associated antigens (and eliminating T lymphocyte tolerance thereto) for treatment of malignancies.
  • Felgner, et al. surmised that muscle cells efficiently take up and express polynucleotides because of the unique structure of muscle tissue, which is comprised of multinucleated calls, sarcoplasmic reticulum and a transverse tubular system which extends deep into the muscle cell.
  • triated muscle is the only tissue found to be capable of taking up and expressing reporter genes that are transferred in the form of plasmid DNA . . . but our findings indicate that fibers damaged by the injection procedure do not take up and express plasmid DNA.” (Davis, et al, Human Gene Therapy, 4:151-159, 1993).
  • intramuscular injections may be effective on at least a short term basis in therapies directed to disease in the muscle tissue itself, it is likely to be less effective in stimulating a tissue specific immune or other biological response to the expressed peptide elsewhere in the patient's body.
  • intramuscular injection is not a particularly viable route for achieving expression of peptides at the primary entry points for many infections; i.e., skin and mucosa.
  • class I restricted antigen that is expressed exclusively in non-hematopoietic cells involves the transfer of that antigen to a host bone marrow derived cell before its presentation.”
  • CTLs cytotoxic T lymphocytes
  • cationic liposomes or a biolistic device i.e., a vaccine "gun” which "shoots" polynucleotides coupled to beads into tissue
  • any invasive means of introducing nucleotides poses problems of tissue trauma (particularly in long-term therapies) and presents limited access to certain target tissues, such as organs.
  • Means for non-invasive delivery of pharmaceutical preparations of peptides have at least the advantage of minimizing tissue trauma.
  • bioavailability of peptides following transdermal or mucosal transmission is limited by the relatively high concentration of proteases in these tissues.
  • reliable means of delivering peptides (such as tumor associated antigens) by transdermal or mucosal transmission of genes encoding for them has been unavailable.
  • cytokine-based immunotherapy has not succeeded in achieving effective treatment of malignancies (see, e.g., Pandoll, Curr. Opin. Immunol., 5:719-725, 1993).
  • CTLs which have developed as class I restricted lymphocytes lyse target cells that express "foreign" peptides bound to their class I MHC molecules.
  • the primary function of class I MHC molecules is apparently to act as conduits for display of endogenous proteins on the surface of APCs as peptide/MHC ligands for appropriate T cell receptors.
  • the display of endogenous peptide/MHC complexes on cell surfaces is essential for targeting lytic activity of CTLs specifically to cells which synthesize new intracellular proteins after viral infection or tumorigenic transformation of cells, as well as for deleting-self-reactive T cells in the thymus (see, e.g., Shastri and Gonzalez, J. Immunol., 150:2724-2736, 1993).
  • Such intracellular expression and antigen presentation is not effectively acheived by extracellular administration of a tumor associated antigen to a host (as in the method described by Quan, et al., supra), nor would it be effectively achieved by introduction of a tumor-associated antigen-encoding polynucleotide into tissue cells, such as muscle cells (as in the method proposed by Felgner, et al., Science, supra, and in PCT application WO 90/11092).
  • T lymphocyte immune tolerance to a self-antigen can be broken by immunizing the host with a mixture of self-antigens and foreign molecular mimics of such antigens (Mamula, et al, J. Immunol., 152:1453-1460, 1994).
  • T lymphocyte immune tolerance to a self-antigen can be broken by immunizing the host with a mixture of self-antigens and foreign molecular mimics of such antigens (Mamula, et al, J. Immunol., 152:1453-1460, 1994).
  • such mixtures fail to induce class I restricted CTL responses in the host because the antigens are expressed extracellularly, rather than in the cytoplasm of APCs.
  • the present invention addresses all of these needs.
  • naked polynucleotide(s) refers to DNA or RNA and can include sense and antisense strands as appropriate to the goals of the therapy practiced according to the invention. Polynucleotide in this context may include oligonucleotides. Naked in this context means polynucleotides which are not complexed to colloidal materials (including liposomal preparations), or contained within a vector which would cause integration of the polynucleotide into the host genome.
  • “Operatively encoding” refers to a polynucleotide which has been modified to include promoter and other sequences necessary for expression and, where desired, secretion of the desired translation product; e.g., a peptide or protein. All the embodiments of the invention can be practiced using known plasmid expression vectors. Preferably, these vectors will include cDNA('s) which encode for the desired translation product. Therefore, unless context otherwise requires, it will be assumed that "polynucleotide” or “naked polynucleotide” refers to operatively encoding sequences contained in a suitable plasmid expression vector, examples of which are provided herein.
  • Matture of polynucleotides shall refer to more than one and up to 200 polynucleotide species which are under the control of the same promoter.
  • Synthesis refers to well-known means of synthesizing polynucleotide sequences and may include isolation and purification of native polynucleotides.
  • Peptide refers to small peptides, polypeptides, oligopeptides and proteins which have a desired biological effect in vivo.
  • “lontophoresis” refers to a known means of transdermal transmission presently used to deliver peptides continuously to a host. More specifically, it is a process that facilitates the transport of ionic species by the application of a physiologically acceptable electrical current. This process and other transdermal transmission means are described in Chien, et al. Transdermal Drug Delivery, “Novel Drug Delivery Systems", Ch. 7, part C, (Marcel Dekker, 1992), the relevant disclosures of which are incorporated herein by this reference for the purpose of illustrating the state of knowledge in the art concerning techniques for drug delivery.
  • Detergents/Absorption Promoters refers to chemical agents which are presently known in the art to facilitate absorption and transfection of certain small molecules, as well as peptides.
  • Antigen Presenting Cells include known APC's such as Langerhans cells, veiled cells of afferent lymphatics, dendritic cells and interdigitating cells of lymphold organs.
  • the definition also includes mononuclear cells such as (1) lymphocytes and macrophages which take up and express polynucleotides according to the invention in skin and (2) mononuclear cells depicted on histological photographs contained herein. These cells are not tissue cells but are likely to be antigen presenting cells.
  • APC's which are known to be present in high numbers in epithelia and thymus dependent areas of the lymphold tissues, including epidermis and the squamous mucosal epithelia of the buccal mucosa, vagina, cervix and esophagus (areas with "relatively high” concentrations of APC's).
  • skin and mucosa as used herein particularly refer to these sites of concentration of APC's.
  • professional APCs shall refer to cells whose primary purpose is antigen presentation; i.e., bone marrow derived cells.
  • Host refers to the recipient of the therapy to be practiced according to the invention.
  • the host may be any vertebrate, but will preferably be a mammal. If a mammal, the host will preferably be a human, but may also be a domestic livestock or pet animal.
  • Target tissue refers to the tissue of the host in which expression of the naked polynucleotide is sought.
  • Skin refers to the epidermal, dermal and subcutaneous tissues of a host.
  • Mucosa refers to mucosal tissues of a host wherever they may be located in the body including, but not limited to, respiratory passages (including bronchial passages, lung epithelia and nasal epithelia), genital passages (including vaginal, penile and anal mucosa), urinary passages (e.g., urethra, bladder), the mouth, eyes and vocal cords.
  • respiratory passages including bronchial passages, lung epithelia and nasal epithelia
  • genital passages including vaginal, penile and anal mucosa
  • urinary passages e.g., urethra, bladder
  • Point of Entry refers to the site of introduction of the naked polynucleotide into a host, including immediately adjacent tissue.
  • Dermat and “Epidermal Administration” mean routes of administration which apply the naked polynucleotide(s) to or through skin. Dermal routes include intradermal and subcutaneous injections as well as transdermal transmission. Epidermal routes include any means of irritating the outermost layers of skin sufficiently to provoke an immune response to the irritant.
  • the irritant may be a mechanical or chemical (preferably topical) agent.
  • Epidermal Administration involves essentially the same method as chemical epidermal administration, except that the chemical irritant is applied to mucosal epithelium.
  • IL refers to interleukin
  • TH1 Response(s) refers to a cellular immune response that is induced preferentially by antigens that bind to and activate certain APC's; i.e., macrophages and dendritic cells.
  • Bioly Active Peptide(s) refers to a peptide which, when administered to a host, exerts a therapeutic benefit or induces an immune response therein.
  • Activating Ligand refers to a ligand which, when bound to a nuclear receptor, induces activity on the part of the receptor.
  • Tumor-associated Antigen(s) refers to embryonic proteins that have been re-expressed by transformed cells or autoantigens that are not truly tumor specific, but are present in mammalian tumor tissue.
  • the invention consists of means of inducing local immunity to an antigen or a systemic response to a therapeutic peptide or polynucleotide by delivering a naked polynucleotide to a host's cells which operatively encodes the antigen or peptide. More particularly, the naked polynucleotide is preferably delivered to a tissue which contains a relatively high concentration of antigen presenting cells as compared to other tissues of the body.
  • the invention will be entirely limited by a particular theory as to the mechanism of expression involved, it is believed that a biological response in these tissues following administration of the naked polynucleotide is achieved because the polynucleotide is expressed intracellulary in the cytoplasm of mononuclear cells, most likely the host's antigen presenting cells. It is also believed that the mononuclear cells may be involved in an inflammatory immune response to the naked polynucleotide once the cells have migrated into the lymph system and presented the expressed peptide as antigen.
  • the target tissue will be skin or mucosa, where approximately 1% to 2% of the cell population is comprised of antigen presenting cells.
  • These tissues are particularly preferred when the therapy is directed to infections or diseases where it is desirable to induce a localized therapeutic or immune response.
  • a mucosal route of administration would be preferred for treatment of sexually transmitted diseases, where the therapy was directed to boosting the immune response to antigens in infected tissues.
  • a nasal route of administration (via inhalation or insufflation) would also be of particular use in therapies directed toward treatment of respiratory and related diseases.
  • the skin and mucosa are also preferred for their regenerative ability, which limits the length of time that introduced materials will remain at the point of entry.
  • the method of the invention may not be as useful for inducing systemic responses to the expressed peptide as it is for inducing a localized response. However, at sufficient dosage levels a transitory systemic effect can be induced.
  • a useful application of this aspect of the invention for induction of systemic responses to the expressed peptide may, therefore, be as an adjuvant for other systemic therapies.
  • the APC's serve as vehicles to deliver the naked polynucelotide to lymphatic organs and to mucosal tissues other than those at the point of entry.
  • This embodiment is illustrated by reference to the following hypothesis; the mechanism described should not, however, be construed as limiting the invention.
  • the APC's take up the naked polynucelotide at or near the point of entry then carry them into lymphatic circulation. Once at a lymph node, the APC will present the intracellularly expressed protein as an antigen, thereby stimulating an immune response. From there, those APC's which carry "homing" receptors for, e.g., mucosa, may reenter lymphatic circulation until they settle in a target tissue other than the tissue at the point of entry. Where desired, homing receptors (specific membrane proteins which bind to target cell ligands) may be sequenced and incorporated into the naked polynucleotide.
  • this embodiment also provides a means of enhancing the host's immune responsiveness by delivering cytokines to increase the concentration of specific cytokines present in the host.
  • increases in the host's levels of circulating cytokines can boost the host's immune response to pathogenic antigens and (1) serve as an adjuvant for vaccines, (2) decrease the immune response to self-antigens in autoimmune diseases, or (3) decrease the immune response to alloantigens (produced, for example, following tissue or organ transplantation).
  • the gene can be administered at an accessible point of entry for expression at a less convenient or accessible site.
  • a naked polynucelotide delivered intranasally may, under appropriate conditions, be expressed in the genital mucosa.
  • Another use for the invention would be in moderating an immune response to an antigen (such as a tumor associated antigen) by immunizing the host against the antigen.
  • an antigen such as a tumor associated antigen
  • the skin and nasal routes of administration, particularly the former, are of particular use in this regard.
  • the method would preferably involve the following steps:
  • the antigen is a self-antigen (as opposed to a tumor-associated antigen from another mammalian species)
  • modification of a polynucleotide which encodes the tumor-associated antigen of interest as a self-antigen to mimic, but not be identical to, the self-antigen.
  • the mutation will substitute or delete a single nucleotide corresponding to the region of the self-antigen which is most immunogeneic.
  • a related aspect of the above-described method is its use in vitro or in an animal model (preferably a primate or rodent) to screen tumor-associated antigen-encoding polynucleotides mutated according to step 2 for their ability to produce tumor-associated antigen specific CTLs in a host.
  • an animal model preferably a primate or rodent
  • Another particular advantage of the invention is that it involves the administration of relatively minute doses of antigen. More specifically, because a polynucleotide that will operatively encode for an antigen is administered in lieu of the antigen itself, the quantity of foreign material being introduced to the host is relatively minimal. Moreover, routes of administration of naked polynucleotides through skin or mucosa require a lower concentration of DNA to produce the same magnitude of immune response than does the intramuscular route of administration (e.g., about 10-50 fold lower; see, e.g., Example X and FIGS. 12-13). As a result, the invention lends itself well to the administration of naked polynucleotides which encode for up to several hundred different antigens for use, as an example, as a polyvalent vaccine.
  • the preferred routes of administration for inducing local immunity in or near the skin will be by transdermal transmission, intradermal injection or superficially scratching or irritating the outermost layer of epidermal cells (i.e., epidermal administration), although subcutaneous injection may also be of use in certain applications.
  • the preferred routes of administration for inducing local immunity in the respiratory tract will be by inhalation or insufflation; routes of administration to other mucosal tissues will vary according to their location.
  • the naked polynucleotides are to be introduced into skin or mucosa
  • delivery of the polynucleotide is preferably facilitated without need for injection by use of detergents, absorption promoters, chemical irritants (such as keratinolytic agents), or mechanical irritants.
  • Detergents and absorption promoters which facilitate uptake of small molecules other than genes are well known in the art and may, without undue experimentation, be adapted for use in facilitating uptake of genes.
  • Another substantially noninvasive approach to introducing the naked polynucleotides is by transdermal transmission (preferably iontophoresis) which has been used with success for transdermal transmission of peptides.
  • any parenteral route of administration is possible, although use of routes involving little or no invasion of host tissues are greatly preferred.
  • intramuscular injections are not preferred. Instead, introduction of the naked polynucleotide(s) to an area of the body which is regenerative, such as skin and mucosa, is preferred for their ability to replace cells which have been directly affected by trauma associated with each dosage.
  • sequences controlling secretion known to those skilled in the art will be included in the administered naked polynucleotide, if not already present in the full-length gene.
  • the antigen for use in immunizing a host to an antigen, it will be preferable for the antigen not to be secreted by APC's in which it is expressed, but rather presented on the cell surface.
  • the naked polynucleotides will preferably be under the control of sequences which prevent secretion of expressed protein, which sequences are known to those of skill in the art.
  • liposomes for delivery of the naked polynucleotides of the invention is not preferred. Rather, such use is likely to result in reduced levels of expression. This phenomenon is likely to be the result of impaired recognition by APC's of a liposome as an antigenic material.
  • FIG. 1 A depicts a section of muscle tissue demonstrating chronic inflammation
  • FIG. 1B depicts a section of muscle tissue displaying myonecrosis following intra-muscular injections of pREVk3 and pRSVIL-2.
  • FIG. 1C depicts sections of similar muscle tissue following subcutaneous injections of pREVK3 or pRSVIL-2.
  • FIG. 2A depicts the results of an ELISA for anti-NP IgG in serum following intradermal injection of naked pCMVRNP
  • FIG. 2B depicts the results of an ELISA for anti-NP IgG in serum following intramuscular injection of naked pCMVRNP.
  • FIG. 3 depicts the results of an ELISA for anti-NP IgG before intranasal introduction of naked pCMVRNP to Balb/c mice.
  • FIG. 4 depicts the results of an ELISA for anti-NP IgG in an unanesthesized group of Balb/c mice.
  • FIG. 5 depicts the results of an ELISA for anti-NP IgG in an anesthesized group of Balb/c mice.
  • FIG. 6 is a photograph of the results of histological studies of skin at the point of entry for pCMVRNP in Balb/c mice showing uptake of the plasmid by mononuclear cells (APC's).
  • An APC is indicated by an arrows; a tissue cell (not containing the plasmid) is indicated by a slashed line.
  • FIG. 7 depicts the results of an ELISA for anti-NP IgG following mechanical epidermal administration of naked pCMVRNP to Balb/c mice.
  • FIG. 8 depicts the results of an ELISA for anti-NP IgG following chemical epidermal administration of naked pCMVRNP to Balb/c mice.
  • FIG. 9 contains a Kaplan-Meyer survival curve depicting the length of time that Balb/c mice injected intradermally with naked pCMVRNP survived following viral challenge.
  • FIG. 10 graphically compares NP gene expression following separate intradermal injections of naked plasmids containing either a CMV or an RSV promoter sequence.
  • FIG. 11 depicts the levels of cytotoxic T cells detected in mice after injection of ovalbumin cDNA and ovalbumin administered by intradermal injection.
  • FIG. 12 depicts the results of an ELISA for anti-ovalbumin antibodies in sera from the mice described with respect to FIG. 12.
  • FIG. 13 depicts the results of an ELISA for anti- ⁇ -galactosidase antibodies after administration of (1) a polynucleotide encoding the enzyme by intramuscular or intradermal injection, and (2) the enzyme by intradermal injection.
  • FIG. 14 depicts the results of an ELISA for anti- ⁇ -galactosidase antibodies in sera from the mice described with respect to FIG. 13 after a booster injection of antigen.
  • FIG. 15 depicts the results of an ELISA for IgG 2A type antibodies in sera for mice (1) injected intradermally or intramuscularly with a polynucleotide encoding ⁇ -galactosidase, or (2) the enzyme by intradermal injection.
  • FIG. 16 depicts the results of an ELISA for IgG 1 type antibodies in sera for mice (1) injected intradermally or intramuscularly with a polynucleotide encoding ⁇ -galactosidase, or (2) the enzyme by intradermal injection.
  • FIG. 17 depicts the results of an ELISA for IgG 2A type antibodies in sera of the mice described With respect to FIG. 25 after a booster injection of antigen.
  • FIG. 18 depicts the results of an ELISA for IgG 1 type antibodies in sera of the mice described with respect to FIG. 24 after a booster injection of antigen.
  • FIG. 19 depicts the results of an ELISA for IgG 1 type antibodies in sera for mice (1) introduced by scratching the skin with tynes coated with a polynucleotide encoding ⁇ -galactosidase, or (2) the enzyme by intradermal injection.
  • FIG. 20 depicts the results of an ELISA for IgG 2A type antibodies in sera for mice (1) introduced by scratching the skin with tynes coated with a polynucleotide encoding ⁇ -galactosidase, or (2) the enzyme by intradermal injection.
  • FIG. 21 is a map of the pGREtk eukaryotic expression vector.
  • FIG. 22 is a map of the pVDRtk eukaryotic expression vector.
  • FIG. 23 depicts the results of an ELISA for levels of IL-2 and INF Y after immunization of mice with an antigen-encoding plasmid (pCMV-Lac-Z) or the antigen itself (( ⁇ galactosidase).
  • FIG. 24 depicts the results of an assay to detect antigen-specific cell lysis by T lymphocytes from mice immunized by epidermal administration of pCMV-NP plasmid.
  • FIG. 25 depicts the results of an assay to detect antigen-specific cell lysis by T lymphocytes from the mice described in FIG. 24 in absence of pulsing of the cells with the antigen.
  • the polynucleotides to be used in the invention may be DNA or RNA, but will preferably be a complementary DNA (cDNA) sequence.
  • the polynucleotide sequences used in the invention must be (a) expressible and (b) either nonreplicating or engineered by means well known in the art so as not to replicate into the host genome. Illustrations of the preparation of polynucleotides suitable for use in the invention follow and specific examples showing how particular polynucleotide compositions were made are provided infra. It will, however, be apparent to those skilled in the art that other known means of preparing nonreplicating polynucleotides may also be suitable.
  • Polynucleotides for use in the invention can be obtained using hybridization methods well known in the art.
  • DNA and RNA may also be synthesized using automated nucleic acid synthesis equipment well known in the art.
  • Use of the well-known polymerase chain reaction (PCR) is particularly preferred for generating mixtures of polynucleotides.
  • Genomic nucleic acids may be prepared by means well-known in the art such as the protocols described in Ausubel, et al., Current Protocols in Molecular Biology, Chs. 2 and 4 (Wiley Interscience, 1989).
  • cDNA can be synthesized according to means well known in the art (see, e.g., Maniatis, et al., Molecular Cloning; A Laboratory Manual (Cold Spring Harbor Lab, N.Y., 1982).
  • a cDNA expression library containing polynucleotides of interest can also be screened by means well known in the art. For reference, examples of such means are illustrated by the discussion below.
  • the naked polynucleotides may operatively encode for therapeutic peptides, but will preferably encode for immunogenic peptides which can act as antigens to provoke a humoral and/or cellular response.
  • the naked polynucleotides can also operatively encode for an antibody.
  • the term "antibody” encompasses whole immunoglobulin of any class, chimeric antibodies, hybrid antibodies with dual or multiple antigen specificities and fragments including hybrid fragments. Also included within the meaning of "antibody” are conjugates of such fragments, and so-called antigen binding proteins (single chain antibodies) as described, for example, in U.S. Pat. No. 4,704,692.
  • the encoded antibodies can be anti-idiotypic antibodies (antibodies that bind other antibodies) as described, for example, in U.S. Pat. No. 4,699,880.
  • the methods of the invention may be adapted for use in administering any polynucleotide or mixture thereof which operatively encode therapeutic and/or immunogenic peptides of interest.
  • the invention is therefore not limited to use with any particular polynucleotide(s).
  • polynucleotide refers to a polymer of deoxyribonucleotides or ribonucleotides, in the form of a separate fragment or as a component of a larger construct.
  • DNA encoding an therapeutic and/or immunogenic peptide of the invention can be assembled from cDNA fragments or from oligonucleotides which provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit.
  • Polynucleotide sequences of the invention include DNA, RNA and cDNA sequences. A polynucleotide sequence can be deduced from the genetic code, however, the degeneracy of the code must be taken into account.
  • Polynucleotides of the invention include sequences which are degenerate as a result of the genetic code, which sequences may be readily determined by those of ordinary skill in the art.
  • Polynucleotide sequences encoding a desired therapeutic and/or immunogenic peptide can be expressed in either eukaryotes or prokaryotes.
  • Hosts can include microbial, yeast, insect and mammalian organisms. Methods of expressing DNA sequences having eukaryotic or viral sequences in prokaryotes are well known in the art. Biologically functional viral and plasmid DNA vectors capable of expression and replication in a host are also well known in the art. Such vectors are used to incorporate DNA of the invention.
  • DNA sequences for use in producing therapeutic and/or immunogenic peptides of the invention can also be obtained by several methods.
  • the DNA can be isolated using hybridization procedures which are well known in the art. These include, but are not limited to: 1) hybridization of probes to genomic or cDNA libraries to detect shared nucleotide sequences; 2) antibody screening of expression libraries to detect shared structural features and 3) synthesis by the polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • DNA sequences encoding or fragments thereof can also be obtained by: 1) isolation of double-stranded DNA sequences from the genomic DNA: 2) chemical manufacture of a DNA sequence to provide the necessary codons for the polypeptide of interest; and 3) in vitro synthesis of a double-stranded DNA sequence by reverse transcription of mRNA isolated from a eukaryotic donor cell. In the latter case, a double-stranded DNA complement of mRNA is eventually formed which is generally referred to as cDNA.
  • Hybridization procedures are useful for the screening of recombinant clones by using labeled mixed synthetic oligonucleotide probes where each probe is potentially the complete complement of a specific DNA sequence in the hybridization sample which includes a heterogeneous mixture of denatured double-stranded DNA.
  • hybridization is preferably performed on either single-stranded DNA or denatured double-stranded DNA.
  • Hybridization is particularly useful in the detection of cDNA clones derived from sources where an extremely low amount of mRNA sequences relating to the polypeptide of interest are present. In other words, by using stringent hybridization conditions directed to avoid non-specific binding, it is possible, for example, to allow the autoradiographic visualization of a specific cDNA clone by the hybridization of the target DNA to that single probe in the mixture.
  • a cDNA library believed to contain a polynucleotide of interest can be screened by injecting various mRNA derived from cDNAs into oocytes, allowing sufficient time for expression of the cDNA gene products to occur, and testing for the presence of the desired cDNA expression product, for example, by using antibody specific for a peptide encoded by the polynucleotide of interest or by using probes for the repeat motifs and a tissue expression pattern characteristic of a peptide encoded by the polynucelotide of interest.
  • a cDNA library can be screened indirectly for expression of therapeutic and/or immunogenic peptides having at least one epitope using antibodies specific for the peptides. Such antibodies can be either polyclonally or monoclonally derived and used to detect expression product indicative of the presence of cDNA of interest.
  • the naked polynucleotides may be conjugated to or used in association with other polynucleotides which operatively code for regulatory proteins that control the expression of these polypeptides or may contain recognition, promoter and secretion sequences.
  • Those of ordinary skill in the art will be able to select regulatory polynucleotides and incorporate them into the naked polynucleotides of the invention (if not already present therein) without undue experimentation.
  • suitable promoters for use in murine or human systems and their use are described in Current Protocols in Molecular Biology, supra at Ch. 1.
  • a particularly preferred form of a naked polynucleotide for use in the invention will be one which has been incorporated into a plasmid vector.
  • Use of a plasmid vector, particularly one which comprises a replicator, will prolong expression of the gene in target tissues.
  • Certain plasmid vectors are also good mediators of immune responses to immunogenic peptides because high levels of expression are achieved when the gene encoding the peptides is incorporated into the vector.
  • Suitable plasmid vectors are well-known in the art and include the vectors described in Current Protocols in Molecular Biology, supra at Ch. 1.
  • Two particularly preferred plasmid vectors are the pRSV (Rous sarcoma virus) and pCMV (cytomegalovirus) promoter vectors.
  • pRSV Raster sarcoma virus
  • pCMV cytomegalovirus
  • CMV CMV is preferred for polynucleotides to be introduced into tissue other than muscle. This preference is based on observations that higher levels of expression are achieved in this context when the CMV promoter is employed.
  • plasmid vector A suitable protocol for isolation of the RSV promotor and its use in construction of a plasmid vector is described in Gorman, et al., Proc. Natl. Acad. Sci, USA, 79:6777, (1982).
  • Other preferred plasmid vectors are pREP7 and pREV which are commercially available from Invitrogen of San Diego, Calif.
  • a particularly suitable plasmid for production of mRNA is the pSP64T cloning vector described by Kreig, et al., Nucleic Acids Res., 12:7057-7070, (1984). Any cDNA containing an initiation codon can be introduced into this plasmid and mRNA prepared from the expressed DNA templates using conventional techniques.
  • a particularly useful vector for administration of any naked polynucleotides according to the invention are those which contain a promoter that can be switched "on” or “off” after the vector has been administered to the patient.
  • nuclear receptors represent a family of transcriptional enhancer factors that act by binding to specific DNA sequences found in target promoters known as response elements. Specific members of the nuclear receptor family include the primary intracellular targets for small lipid-soluble ligands, such as vitamin D 3 and retinoids, as well as steroid and thyroid hormones ("activating ligands").
  • Nuclear receptors activated by specific activating ligands are well suited for use as promoters in eukaryotic expression vectors since expression of genes can be regulated simply by controlling the concentration of ligand available to the receptor.
  • glucocorticoid-inducible promoters such as that of the long terminal repeat of the mouse mammary tumor virus (MMTV) have been widely used in this regard because the glucocorticoid response elements are expressed in a wide variety of cell types.
  • glucocorticoid response elements responsive to a wide variety of steroid hormones e.g., dexamethasone and progesterone
  • a pGREtk plasmid containing one or more rat tyrosine amino transferase glucocorticoid response elements upstream of the herpes simplex virus thymidine kinase (tk) promoter in pBLCAT8+
  • tk herpes simplex virus thymidine kinase
  • the pGREtk promoter (see, map at FIG. 20) is particularly effective in stimulating controlled overexpression of cloned genes in eukaryotic cells (Mader and White, supra at 5607).
  • vitamin D 3 activating ligands are particularly suitable NRRE promoters for use in the invention.
  • NRRE promoters inducible by vitamin D 3 activating ligands contain the vitamin D 3 receptor (VDR) response elements PurG(G/T)TCA which recognizes direct repeats separated by 3 base pairs.
  • Vitamin D 3 response elements are found upstream of human osteocalcin and mouse osteopontin genes; transcription of these genes is activated on binding of the VDR (see, e.g., Morrison and Eisman, J. Bone Miner.
  • Ferrara, et al. also described vitamin D 3 inducible promoters in recombinant expression vectors constructed using multiple copies of a strong VDR; in particular, the mouse osteopontin VDR (composed of a direct repeat of PurGTTCA motifs separated by 3 base pairs).
  • This VDR conforms to the PurGG/TTCA consensus motifs which have previously been shown to be responsive not only to vitamin D 3 , but also to thyroid hormone and/or retinoic acid.
  • As many as three copies of the mouse VDR was inserted into pBLCAT8+; immediately upstream of the herpes simplex virus tk promoter (see, e.g., FIG. 21 map of pVDREtk!).
  • VDREtk vector into COS cells (producing a "VDR expression system") proved to be particularly useful in that COS cells contain the nuclear retinoid X receptor (RXR) that has been shown to act as an auxiliary factor for binding of VDR to its response element.
  • RXR nuclear retinoid X receptor
  • the VDR expression system (and functionally equivalent expression systems under the control of, for example, human osteocalcin gene promoter) is uniquely suited for use in the invention.
  • expression of a naked polynucleotide administered to a mammal according to the invention by epidermal or dermal routes (particularly the former) in a vitamin D 3 responsive expression system can be switched on by topical administration of a 1,25-dihydroxyvitamin D 3 preparation at the point of entry (and off by withdrawing the vitamin D 3 preparation and/or modulated by applying or withdrawing a source of retinoic acid to or from the point of entry).
  • 1,25-dihydroxyvitamin D 3 and nonhypercalcemic analogs thereof have been approved for use in topical preparations by the United States Food and Drug Administration for the treatment of psoriasis and are commercially available.
  • NRRE promoters In vivo tests of the NRRE promoters indicate that they are inducible on systemic exposure to their corresponding response elements (see, Tsou, et al. Exp. Cell Res., 214:27-34, 1994). Given the expected retention of polynucleotides administered dermally or epidermally at the point of entry (thus making them available for exposure to topically absorbed response elements; see, e.g., discussion at pages 15-16 and data in Example IV), it can be reasonably predicted that use of NRRE promoters for expression of such polynucleotides will also permit their in vivo control through topical administration of appropriate NRRE promoter activating ligands (e.g., 1,25-dihydroxyvitamin D 3 transcriptional activators with a VDR expression vector for expression of the polynucleotide of interest).
  • appropriate NRRE promoter activating ligands e.g., 1,25-dihydroxyvitamin D 3 transcriptional activators with a V
  • an NRRE promoter recombinant expression vector for administration and expression of naked polynucleotides according to the invention permits control of expression to, for example, switch on expression when dosing is needed or switch off expression in the event of an adverse reaction to the expressed protein or peptide.
  • RNA virus such as a retrovirus
  • retroviral vector is a derivative of a murine or avian retrovirus.
  • retroviral vectors in which a single foreign gene can be inserted include, but are not limited to: Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV).
  • MoMuLV Moloney murine leukemia virus
  • HaMuSV Harvey murine sarcoma virus
  • MuMTV murine mammary tumor virus
  • RSV Rous Sarcoma Virus
  • a number of additional retroviral vectors can incorporate multiple genes. All of these vectors can transfer or incorporate a gene for a selectable marker so that transduced cells can be identified and generated.
  • Retroviral vectors can be made target specific by inserting, for example, a polynucleotide encoding a sugar, a glycolipid, or a protein. Preferred targeting is accomplished by using an antibody to target the retroviral vector.
  • a polynucleotide encoding a sugar, a glycolipid, or a protein Preferred targeting is accomplished by using an antibody to target the retroviral vector.
  • a separate vector can be utilized for targeted delivery of a replacement gene to the cell(s), if needed.
  • an antisense oligonucleotide and the replacement gene may also be delivered via the same vector since the antisense oligonucleotide is specific only for target gene containing a polymorphism.
  • helper cell lines that contain plasmids encoding all of the structural genes of the retrovirus under the control of regulatory sequences within the LTR. These plasmids are missing a nucleotide sequence that enables the packaging mechanism to recognize an RNA transcript for encapsidation.
  • Helper cell lines that have deletions of the packaging signal include, but are not limited to, ⁇ 2, PA317 and PA12, for example. These cell lines produce empty virions, since no genome is packaged. If a retroviral vector is introduced into such helper cells in which the packaging signal is intact, but the structural genes are replaced by other genes of interest, the vector can be packaged and vector virion can be produced.
  • these vectors may be modified to include known reporter genes.
  • the pRSV lac-Z DNA vector described in Norton, et al., Mol. Cell. Biol., 5:281, (1985) may produce ⁇ -galactosidase with protein expression.
  • Luciferase and chloramphenicol acetyl transferase (“CAT”; see, e.g., Gorman, et al., supra, re construction of a pRSV-CAT plasmid) may also be used.
  • Convenient plasmid propogation may be obtained in E. coli (see, e.g., Molecular Cloning: A Laboratory Manual, supra.)
  • a mixture of polynucleotides or separately coadministered group of polynucleotides may include a gene operatively encoding for an immunosuppressive cytokine (such as TGF ⁇ ) and a separate gene operatively encoding for a relevant histocompatibility protein.
  • an immunosuppressive cytokine such as TGF ⁇
  • a separate gene operatively encoding for a relevant histocompatibility protein may be used as a tolerizing vaccine.
  • compositions of naked polynucleotides and mixtures of polynucleotides may be placed into a pharmaceutically acceptable suspension, solution or emulsion.
  • Suitable mediums include saline and may, for those embodiments which do not rely on antigen presenting cells for delivery of the polynucleotides into target tissue, liposomal preparations.
  • pharmaceutically acceptable carriers may include sterile aqueous of non-aqueous solutions, suspensions, and emulsions.
  • non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
  • Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils.
  • Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, antioxidants, chelating agents, and inert gases and the like. Further, a composition of naked polynucleotides may be lyophilized using means well known in the art, for subsequent reconstitution and use according to the invention.
  • a colloidal dispersion system may also be used for targeted delivery.
  • the advantages of employing the method of the invention to administer naked nucleotides, and of administering those nucleotides to tissues having relatively high concentrations of antigen presenting cells are such that the use of collodidal dispersion systems for delivery of polynucleotides will not be a preferred method. The discussion below regarding such systems is therefore provided principally for reference in the event that the preferred method of the invention is determined to be unavailable for use with respect to a particular indication.
  • Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes.
  • the preferred colloidal system of this invention is a liposome.
  • Liposomes are artificial membrane vesicles which are useful as delivery vehicles in vitro and in vivo. It has been shown that large unilamellar vesicles (LUV), which range in size from 0.2-4.0 ⁇ m can encapsulate a substantial percentage of an aqueous buffer containing large macromolecules. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, et al., Trends Biochem. Sci., 6:77, 1981). In addition to mammalian cells, liposomes have been used for delivery of polynucleotides in plant, yeast and bacterial cells.
  • LUV large unilamellar vesicles
  • a liposome In order for a liposome to be an efficient gene transfer vehicle, the following characteristics should be present: (1) encapsulation of the genes encoding the antisense polynucleotides at high efficiency while not compromising their biological activity; (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4) accurate and effective expression of genetic information (Mannino, et al., Biotechniques, 6:682, 1988).
  • the composition of the liposome is usually a combination of phospholipids, particularly high-phase-transition-temperature phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used.
  • the physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations.
  • lipids useful in liposome production include phosphatidyl compounds, such as phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebrosides, and gangliosides. Particularly useful are diacylphosphatidylglycerols, where the lipid moiety contains from 14-18 carbon atoms, particularly from 16-18 carbon atoms, and is saturated.
  • Illustrative phospholipids include egg phosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.
  • the targeting of liposomes can be classified based on anatomical and mechanistic factors.
  • Anatomical classification is based on the level of selectivity, for example, organ-specific, cell-specific, and organelle-specific.
  • Mechanistic targeting can be distinguished based upon whether it is passive or active. Passive targeting utilizes the natural tendency of liposomes to distribute to cells of the reticulo-endothelial system (RES) in organs which contain sinusoidal capillaries.
  • RES reticulo-endothelial system
  • Active targeting involves alteration of the liposome by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein, or by changing the composition or size of the liposome in order to achieve targeting to organs and cell types other than the naturally occurring sites of localization.
  • a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein
  • the surface of the targeted delivery system may be modified in a variety of ways.
  • lipid groups can be incorporated into the lipid bilayer of the liposome in order to maintain the targeting ligand in stable association with the liposomal bilayer.
  • Various linking groups can be used for joining the lipid chains to the targeting ligand.
  • liposomal preparations substantially limit uptake of the naked polynucleotides in vivo and should not be used. Instead, isotonic buffered solution is the preferred medium for maximal uptake of the naked polynucleotides in such embodiments. Further, use of absorption promoters, detergents, chemical irritants or mechanical irritation means is also preferred to enhance transmission of the naked polynucleotide composition through the point of entry. For reference concerning general principles regarding promoters and detergents which have been used with success in mucosal delivery of organic and peptide-based drugs, see Chien, Novel Drug Delivery Systems, Ch. 4 (Marcel Dekker, 1992).
  • the means of introduction may be by epidermal administration, subcutaneous or intradermal injection. Of these means, epidermal administration is preferred for the greater concentrations of APC's expected to be in intradermal tissue.
  • the means of introduction for dermal routes of administration which are most preferred, however, are those which are least invasive. Preferred among these means are transdermal transmission and epidermal administration.
  • Iontophoresis is a suitable method. Iontophoretic transmission may be accomplished using commercially available "patches" which deliver their product continuously through unbroken skin for periods of several days or more. Use of this method allows for controlled transmission of pharmaceutical compositions in relatively great concentrations, permits infusion of combination drugs and allows for contemporaneous use of an absorption promoter.
  • An exemplary patch product for use in this method is the LECTRO PATCH trademarked product of General Medical Company of Los Angeles, Calif. This product electronically maintains reservoir electrodes at neutral pH and can be adapted to provide dosages of differing concentrations, to dose continuously and/or to dose periodically. Preparation and use of the patch should be performed according to the manufacturer's printed instructions which accompany the LECTRO PATCH product; those instructions are incorporated herein by this reference.
  • Epidermal administration essentially involves mechanically or chemically irritating the outermost layer of the epidermis sufficiently to provoke an immune response to the irritant. Specifically, the irritation should be sufficient to attract APC's to the site of irritation. As discussed previously, it is believed that the APC's then take up and express the administered naked polynucleotide.
  • An exemplary mechanical irritant means employs a multiplicity of very narrow diameter, short tynes which can be used to irritate the skin and attract APC's to the site of irritation, to take up naked polynucleotides transferred from the end of the tynes.
  • a multiplicity of very narrow diameter, short tynes which can be used to irritate the skin and attract APC's to the site of irritation, to take up naked polynucleotides transferred from the end of the tynes.
  • MONO-VACC old tuberculin test manufactured by Pastuer Merieux of Lyon, France contains a device suitable for introduction of naked polynucleotides.
  • the device (which is distributed in the U.S. by Connaught Laboratories, Inc. of Swiftwater, Pa.) consists of a plastic container having a syringe plunger at one end and a tyne disk at the other.
  • the tyne disk supports a multiplicity of narrow diameter tynes of a length which will just scratch the outermost layer of epidermal cells.
  • Each of the tynes in the MONO-VACC kit is coated with old tuberculin; in the present invention, each needle is coated with a pharmaceutical composition of naked polynucleotide or a mixture thereof.
  • Use of the device is according to the manufacturer's written instructions included with the device product; these instructions regarding use and administration are incorporated herein by this reference to illustrate conventional use of the device. Similar devices which may also be used in this embodiment are those which are currently used to perform allergy tests.
  • Another suitable approach to epidermal administration of naked polynucleotides is by use of a chemical which irritates the outermost cells of the epidermis, thus provoking a sufficient immune response to attract APC's to the area.
  • a chemical which irritates the outermost cells of the epidermis thus provoking a sufficient immune response to attract APC's to the area.
  • An example is a keratinolytic agent, such as the salicylic acid used in the commercially available topical depilatory creme sold by Noxema Corporation under the trademark NAIR.
  • This approach may also be used to achieve epithelial administration in the mucosa.
  • the chemical irritant may also be applied in conjunction with the mechanical irritant (as, for example, would occur if the MONO-VACC type tyne were also coated with the chemical irritant).
  • the naked polynucleotide may be suspended in a carrier which also contains the chemical irritant or coadministered there
  • the means of introduction will vary according to the location of the point of entry. Particularly for immunization to and treatment of respiratory infections, intranasal administration means are most preferred. These means include inhalation of aerosol suspensions or insufflation of the naked polynucleotide or mixtures thereof. Suppositories and topical preparations will also be suitable for introduction to certain mucosa, such as genital and ocular sites. Also of particular interest with respect to vaginal delivery of naked polynucleotides are vaginal sandwich-type rings and pessaries. Examples of these devices and their use are described in Chien, supra at Ch.9.
  • each naked polynucleotide or mixture thereof to be supplied using the method of the invention will vary depending on the desired response by the host and the polynucleotide used. Generally, it is expected that up to 100-200 ⁇ g of DNA can be administered in a single dosage, although as little as about 0.3 ⁇ g of DNA administered through skin or mucosa can induce long lasting immune responses.
  • the naked polynucleotides be supplied at a dosage sufficient to cause expression of the biologically active peptide encoded by the polynucleotide.
  • Dosages suitable for particular indications e.g., supplying a subtherapeutic dosage of cytokine are illustrated by the discussion and examples provided below.
  • dosages may be modified to achieve therapeutic, subtherapeutic or immunogenic levels of expression.
  • Means to confirm the presence and quantity of expressed peptides are well-known to those skilled in the art and will not, therefore, be described in detail. Certain such means are illustrated in the Examples provided below; generally, they include immunoassays (such as enzyme-linked immunosorbent assays), PCR techniques, and immunohistological analyses performed according to techniques which are well known in the art. Dosages of the administered polynucleotides can be adjusted to achieve the desired level of expression based on information provided by these detection and quantification means as well as in vivo clinical signs known to practitioners skilled in the clinical arts.
  • Another aspect of the invention is the administration of a peptide cocktail (i.e., mixture of polynucleotides) via expression of gene constructs containing, for example, up to 200 polynucleotide sequences under the control of a single promoter.
  • a cocktail vaccine could be administered according to the method of the invention which is capable of stimulating an immune response to many different rhinoviruses.
  • This approach also allows for the construction of a vaccine to various strains of HIV, using pooled isolates of envelope genes from different patients (which genes may, if necessary, then be amplified).
  • a naked polynucleotide operatively encoding for an immunogenic peptide may be coupled to or administered with a naked polynucleotide operatively encoding an antibody in such a way that both peptide and antibody will be expressed.
  • IL-2 and anti-gp71 may (based on results obtained with the IL-2 protein) result in localization of the antibody in tumor tissue developed in response to murine leukemia virus (MuLV) in mice (see, re results obtained with concurrent administration of IL-2 /anti-gp71 mAb's, Schultz, et al., Cancer Res., 50:5421-5425, 1990).
  • This embodiment of the invention is based on the principle that peptides encoded by naked polynucleotides administered to tissues having a relatively high concentration of APCs according to the invention will be expressed intracellularly in the APCs (which then migrate into lymphatic tissue and stimulate an immune response).
  • the method of the invention is particularly well suited to achieve intracellular expression of immunoreactive target antigens that will stimulate the development of antigen-specific class I restricted CTLs useful in cancer immunotherapy.
  • the method of the invention could be applied to generate CTLs against tumor-associated antigens on cells of an intact tumor, the method can be expected to have greatest efficacy when applied toward inducing CTL activity against residual cancer cells after removal of the primary tumor or organ associated with the tumor (where the latter is not required for life, such as endocrine and exocrine glands, sex organs, regions of the gastrointestinal tract and skin).
  • organ-specific or carcino-embryonic, tumor-associated antigen encoding polynucleotides will be selected or, if not known, identified.
  • organ-specific, tumor-associated antigens whose cDNA coding sequences are known to those of ordinary skill in the art include the prostate-specific, transmembrane protein (PSM) (see, Israeli, et al., Cancer Res., 54:1807-1811, 1994 and 53:227-230, 1993); breast eptithelial antigens (see, Ceriani, et al., Anal.
  • PSM prostate-specific, transmembrane protein
  • breast eptithelial antigens see, Ceriani, et al., Anal.
  • Carcino-embryonic antigen which is localized to epithelia of the intestinal lumen; see, Benchimol, et al., Cell, 57:327-324, 1989
  • the antigen associated with Wilm's tumor which is localized in kidney; see, Roth, et al., Verh. Dtsch. Ges. Pathol., 73:372-387, 1989
  • carcino-embryonic tumor associated antigens for which cDNA coding sequences are known and are suitable for use in the method of the invention.
  • Another method suitable for identification and isolation of genes uses the PCR to identify differentially expressed mRNAs is described in Liang and Pardee, Science, 257:967-971, 1992.
  • This method uses a set of oligonucleotide primers, one being anchored to the polyadenylate tail of a subset of mRNAs, the other being short and arbitrary in sequence so that it anneals at different positions relative to the first primer.
  • the mRNA subpopulations defined by these primer pairs are amplified after reverse transcription and resolved on a DNA sequencing gel.
  • the authors report that they were able to obtain reproducible patterns of amplified complementary DNA fragments that showed strong dependence on sequence specificity in either primer of a primer pair.
  • detection of targeted polynucleotides in samples or libraries by PCR involves the use of primers which embrace oligonucleotides of sufficient length and appropriate sequence to provide specific initiation of polymerization of a significant number of nucleic acid molecules containing the target nucleic acid under the conditions of stringency for the reaction utilizing the primers. In this manner, it is possible to selectively amplify the specific target nucleic acid sequence containing the nucleic acid of interest.
  • the term "primer” as used herein refers to a sequence comprising two or more deoxyribonucleotides or ribonucleotides, preferably at least eight, which sequence is capable of initiating synthesis of a primer extension product that is substantially complementary to a target nucleic acid strand.
  • the oligonucleotide primer typically contains 15-22 or more nucleotides, although it may contain fewer nucleotides as long as the primer is of sufficient specificity to allow essentially only the amplification of the specifically desired target nucleotide sequence (i.e., the primer is substantially complementary).
  • primer synthesis include the presence of nucleoside triphosphates and an agent for polymerization, such as DNA polymerase, and a suitable temperature and pH.
  • the primer is preferably single stranded for maximum efficiency in amplification, but may be double stranded. If double stranded, the primer is first treated to separate its strands before being used to prepare extension products.
  • the primer is an oligodeoxyribonucleotide.
  • the primer must be sufficiently long to prime the synthesis of extension products in the presence of the inducing agent for polymerization. The exact length of primer will depend on many factors, including temperature, buffer, and nucleotide composition.
  • Primers used for PCR detection of tumor-associated antigens will be designed to be "substantially" complementary to each strand of nucleotide sequence to be amplified.
  • Substantially complementary means that the primers must be sufficiently complementary to hybridize with their respective strands under conditions which allow the agent for polymerization to function.
  • the primers should have sufficient complementarily with the flanking sequences to hybridize therewith and permit amplification of the mutant nucleotide sequence.
  • the 3' terminus of the primer that is extended has perfectly base paired complementarity with the complementary flanking strand.
  • Oligonucleotide primers are employed in any amplification process that produces increased quantities of target nucleic acid.
  • one primer is complementary to the negative (-) strand of the mutant nucleotide sequence and the other is complementary to the positive (+) strand.
  • Annealing the primers to denatured nucleic acid followed by extension with an enzyme, such as the large fragment of DNA Polymerase I (Klenow) or Taq DNA polymerase and nucleotides or ligases results in newly synthesized +and -strands containing the target nucleic acid.
  • the product of the amplification reaction is a discrete nucleic acid duplex with termini corresponding to the ends of the specific primers employed. Those of skill in the art will know of other amplification methodologies which can also be utilized to increase the copy number of target nucleic acid.
  • oligonucleotide primers for use in the invention may be prepared using any suitable method, such as conventional phosphotriester and phosphodiester methods or automated embodiments thereof.
  • diethylphosphoramidites are used as starting materials and may be synthesized as described by Beaucage, et al. (Tetrahedron Letters, 22,:1859-1862, 1981).
  • One method for synthesizing oligonucleotides on a modified solid support is described in U.S. Pat. No. 4,458,066.
  • One method of amplification which can be used according to this invention is the polymerase chain reaction (PCR) described in U.S. Pat. Nos. 4,683,202 and 4,683,195.
  • the nucleic acid from any histologic tissue specimen, in purified or nonpurified form can be utilized as the starting nucleic acid or acids, provided it contains, or is suspected of containing, the specific nucleic acid sequence containing the target nucleic acid.
  • the process may employ, for example, DNA or RNA, including messenger RNA (mRNA), wherein DNA or RNA may be single stranded or double stranded.
  • mRNA messenger RNA
  • enzymes, and/or conditions optimal for reverse transcribing the template to DNA would be utilized.
  • a DNA-RNA hybrid which contains one strand of each may be utilized.
  • a mixture of nucleic acids may also be employed, or the nucleic acids produced in a previous amplification reaction herein, using the same or different primers may be so utilized.
  • the nucleotide sequence to be amplified may be a fraction of a larger molecule or can be present initially as a discrete molecule, such that the specific sequence constitutes the entire nucleic acid. It is not necessary that the sequence to be amplified be present initially in a pure form; it may be a minor fraction of a complex mixture, such as contained in whole human DNA.
  • Strand separation can be effected either as a separate step or simultaneously with the synthesis of the primer extension products. This strand separation can be accomplished using various suitable denaturing conditions, including physical, chemical, or enzymatic means; the word "denaturing" includes all such means.
  • One physical method of separating nucleic acid strands involves heating the nucleic acid until it is denatured. Typical heat denaturation may involve temperatures ranging from about 80° to 105° C. for times ranging from about 1 to 10 minutes.
  • Strand separation may also be induced by an enzyme from the class of enzymes known as helicases or by the enzyme RecA, which has helicase activity, and in the presence of riboATP which is known to denature DNA.
  • the reaction conditions suitable for strand separation of nucleic acids with helicases are described by Kuhn Hoffmann-Berling (CSH-Quantitative Biology, 43:63, 1978) and techniques for using RecA are reviewed in C. Radding (Ann. Rev. Genetics, 16:405-437, 1982).
  • nucleic acid containing the target nucleic acid to be amplified is single stranded
  • its complement is synthesized by adding one or two oligonucleotide primers.
  • a primer extension product is synthesized in the presence of primer, an agent for polymerization, and the four nucleoside triphosphates described below.
  • the product will be complementary to the single-stranded nucleic acid and will hybridize with a single-stranded nucleic acid to form a duplex of unequal length strands that may then be separated into single strands to produce two single separated complementary strands.
  • two primers may be added to the single-stranded nucleic acid and the reaction carried out as described.
  • the separated strands are ready to be used as a template for the synthesis of additional nucleic acid strands.
  • This synthesis is performed under conditions allowing hybridization of primers to templates. Generally synthesis occurs in a buffered aqueous solution, preferably at a pH of 7-9, most preferably about 8.
  • a molar excess for genomic nucleic acid, usually about 10 8 :1 primer:template
  • a molar excess for genomic nucleic acid, usually about 10 8 :1 primer:template
  • the amount of complementary strand may not be known if the process of the invention is used for diagnostic applications, so that the amount of primer relative to the amount of complementary strand cannot be determined with certainty.
  • the amount of primer added will generally be in molar excess over the amount of complementary strand (template) when the sequence to be amplified is contained in a mixture of complicated long-chain nucleic acid strands. A large molar excess is preferred to improve the efficiency of the process.
  • the substrates for example, the deoxyribonucleotide triphosphates dATP, dCTP, dGTP, and dTTP
  • the substrates are added to the synthesis mixture, either separately or together with the primers, in adequate amounts and the resulting solution is heated to about 90°-100° C. from about 1 to 10 minutes, preferably from 1 to 4 minutes. After this heating period, the solution is allowed to cool to room temperature, which is preferable for the primer hybridization.
  • an appropriate agent for effecting the primer extension reaction (called herein "agent for polymerization"), and the reaction is allowed to occur under conditions known in the art.
  • the agent for polymerization may also be added together with the other reagents if it is heat stable. This synthesis (or amplification) reaction may occur at room temperature up to a temperature above which the agent for polymerization no longer functions. Thus, for example, if DNA polymerase is used as the agent, the temperature is generally no greater than about 40° C.
  • the agent for polymerization may be any compound or system which will function to accomplish the synthesis of primer extension products, including enzymes.
  • Suitable enzymes for this purpose include, for example, E. coli DNA polymerase I, Taq polymerase, Klenow fragment of E. coli DNA polymerase I, T4 DNA polymerase, other available DNA polymerases, polymerase muteins, reverse transcriptase, ligase, and other enzymes, including heat-stable enzymes (i.e., those enzymes which perform primer extension after being subjected to temperatures sufficiency elevated to cause denaturation).
  • Suitable enzymes will facilitate combination of the nucleotides in the proper manner to form the primer extension products which are complementary to each mutant nucleotide strand.
  • the synthesis will be initiated at the 3' end of each primer and proceed in the 5' direction along the template strand, until synthesis terminates, producing molecules of different lengths.
  • agents for polymerization may be agents for polymerization, however, which initiate synthesis at the 5' end and proceed in the other direction, using the same process as described above.
  • the newly synthesized mutant nucleotide strand and its complementary nucleic acid strand will form a double-stranded molecule under hybridizing conditions described above and this hybrid is used in subsequent steps of the process.
  • the newly synthesized double-stranded molecule is subjected to denaturing conditions using any of the procedures described above to provide single-stranded molecules.
  • the steps of denaturing and extension product synthesis can be repeated as often as needed to amplify the target mutant nucleotide sequence to the extent necessary for detection.
  • the amount of the mutant nucleotide sequence produced will accumulate in an exponential fashion.
  • the amplified product may be detected by Southern blot analysis, without using radioactive probes.
  • a small sample of DNA containing a very low level of target nucleotide sequence is amplified, and analyzed via a Southern blotting technique.
  • the use of non-radioactive probes or labels is facilitated by the high level of the amplified signal.
  • Polynucleotides detected as described above can be further evaluated, detected, cloned, sequenced, and the like, either in solution or after binding to a solid support, by any method usually applied to the detection of a specific DNA sequence such as PCR, oligomer restriction (Saiki, et al., Bio/Technology, 3:1008-1012, 1985), allele-specific oligonucleotide (ASO) probe analysis (Conner, et al., Proc. Natl. Acad. Sci. USA, 80:278, 1983), oligonucleotide ligation assays (OLAs) (Landegren, et al., Science, 241:1077, 1988), and the like. Molecular techniques for DNA analysis have been reviewed and are well known in the art (Landegren, et al., Science, 242:229-237, 1988).
  • the antigen is a self-antigen (as opposed to a tumor-associated antigen from another mammalian species)
  • modification of a polynucleotide which encodes the tumor-associated antigen of interest as a self-antigen to mimic, but not be identical to, the self-antigen.
  • the invention therefore provides a method for identifying which mutations in a tumor-associated antigen-encoding polynucleotide will be effective in modifying a self-tumor-associated antigen to an extent sufficient to break T lymphocyte tolerance thereto in a host (i.e., mutations which will produce immunoreactive "mimic" antigens for stimulation of specific autoimmune T lymphocyte responses).
  • tumor-associated self-antigen-encoding polynucleotides will be mutated as described below.
  • the mutation will be made in the region of the polynucleotide which codes for an immunogeneic region of the self-antigen; i.e., for T cell epitope(s) in the self-antigen.
  • T cell epitopes Although more laborious means of mapping T cell epitopes are known in the art, conveniently, epitopic regions of a protein can be predicted using Berzofsky's algorithm (see, Margalit, et al., J. Immunol., 138:2213-2229, 1987, the disclosure of which is incorporated by this reference to illustrate knowledge in the art concerning the use of Berzofsky's algorithm).
  • the algorithm screens overlapping amino acid residues in a protein and predicts the presence and location of T cell epitope(s) based on the ability of sets of residues to form an amphiphatic alphahelix configuration. The higher the amphiphatic score for a predicted epitope, the greater its probable immuoreactivity.
  • a software program for applying the algorithm to amino acid sequences in a protein is commercially available under the tradename AMPHI program and is commonly used in the art to predict T cell epitopes.
  • Rotzschike and co-workers have also recently described a method which they characterize as permitting "exact" prediction of a T cell epitope (Rotzschike, et al., Eur. J. Immunol., 21:2431, 1991).
  • mutated polynucleotides which operatively encode mimic antigens can be produced, tested and/or administered according to the methods of the invention for use in cancer immunotherapy.
  • suitable mutations include generation of a restriction fragment length polymorphism (RFLP), a nucleotide deletion, a nucleotide substitution, or any other mammalian nucleic acid sequence of interest.
  • RFLP restriction fragment length polymorphism
  • mutant or mutated as applied to a polynucleotide sequence shall be understood to encompass a mutation, a restriction fragment length polymorphism, a nucleic acid deletion, or a nucleic acid substitution which render a tumor-associated antigen immunoreactive in the host.
  • Particularly preferred mutations will be those which render a self-antigen similar in primary structure to a cross-reactive antigen from a different mammalian species (e.g., mouse and human ribonucleoproteins; see, e.g., Mamula, et al., J. Immunol., 152:1453-1461, 1994).
  • immunoreactive mimic tumor-associated antigens produced by modification of self-antigens will be referred to as “homogenous tumor-associated antigen mimics", while tumor-associated antigens from a species other than the host species (which are immunologically similar to the tumor-associated antigens present on tumor cells in the host species) will be referred to as “hetereogenous tumor-associated antigen mimics”.
  • a tumor-associated antigen-encoding polynucleotide having a desirable mutation may be produced by site-specific mutagenesis using a conventional polymerase chain reaction (PCR) and a primer pair corresponding to the 3' and 5' regions of the cDNA.
  • PCR polymerase chain reaction
  • a preferred method of mutation-generating PCR amplification is the overlap extension PCR technique described by Ho, et al., Gene 77:51-59 (1989), the disclosure of which is incorporated herein by this reference.
  • this technique accomplishes site-specific mutagenesis of the clone by utilizing a 3' primer to add the mismatched mutating bases (primer B in the Ho article, which is used with the 5' primer A in the first PCR cycle described).
  • Amplification using the A and B primers yields an AB fragment.
  • a second PCR cycle uses a primer (D) from the 3' end of the gene and a 5' mutated primer (C) complementary to primer B.
  • the resulting amplification product (fragment CD) will overlap the AB fragment.
  • the resulting fusion product AD will contain the full-length cDNA sequence and the desired mutation.
  • a PCR method modified to decrease the fidelity of Taq polymerase during DNA synthesis is particularly useful.
  • the PCR is performed under conditions that will generally produce a cumulative error frequency of 2% over the entire DNA nucleotide sequence and a mutant yield (for targets over 300 bp) of greater than 90%; to wit, conditions of high and pool-biased dNTP concentrations (1 mM each dTTP, dCTP, dGTP, 200 ⁇ M dATP), a high concentration of MgCl 2 in the presence of Mncl 2 (0.5 mM), and 25 PCR cycles starting with 1 ng cloned plasmid target.
  • Suitable techniques and vectors for use in this step of the invention are well-known to those of ordinary skill in the art or can be ascertained without undue experimentation; see, e.g., the review and discussion at Sections I(A) and II, supra.
  • tumor-associated antigen mimics have been (a) identified according to step 1 above; and, (b) produced by expression using the polynucleotides and recombinant expression vectors constructed according to steps 2 and 3 above; or, (b') synthesized using conventional peptide synthesis methods, the mimics will preferably be screened for their ability to stimulate autoimmunoreactive CTLs which will lyse tumor cells which have the target tumor-antigen on the cell surface.
  • tumor-associated antigen mimics suitable for use in cancer immunotherapy will be those which will form peptide/MHC complexes on the surface of APCs in vivo.
  • Peptides bound to class I MHC molecules on APCs are believed to be characterized by having a length of about 8 to 10 amino acid residues (see, e.g., Falk, et al., Nature, 351:290, 1991; and, Jardetzky, et al., Nature, 353:326, 1991).
  • the invention provides a method for determining whether a candidate tumor-associated antigen-encoding polynucleotide has "therapeutic efficacy"; i.e., will express a tumor-associated antigen mimic in the cytoplasm of APCs, which antigen will in turn (a) become bound to class I MHC molecules on the APC cell surface; and (b) stimulate CTL lysis of host tumor cells bearing the target tumor-associated antigen.
  • a candidate tumor-associated antigen mimic recombinantly expressed in APCs will become bound to class I MHC
  • conventional techniques such as mass spectrometric analysis of transfected APCs may be used.
  • another technique which is preferred for its convenience involves transfection of MHC expressing CHO (chinese hamster ovary) cells as model APC with a candidate tumor-associated antigen mimic encoding polynucleotide.
  • MHC expressing CHO (chinese hamster ovary) cells as model APC with a candidate tumor-associated antigen mimic encoding polynucleotide.
  • murine and non-human primate animal models will be suitable for predicting in vivo CTL responses to APCs transfected in vivo according to the method of the invention; i.e., whether such APCs can stimulate CTL responses against tumor-associated antigens on tumor cells in the host.
  • one model for determining antigen-specific CTL activity involves the use of recipient mice without endogenous active T lymphocytes; e.g., nude mice or irradiated mice.
  • Adoptive transfer of tumor-associated antigen primed CTLs into mice in whom tumor cells from a host or cell line have been introduced allows for in vivo assessment of the lytic ability of the transferred CTLs vis-a-vis the tumor cells (see, e.g., the standard protocols for adoptive transfer, CTL depletion and in vivo T cell activity assays described in Coligan, et al., "Current Protocols in Immunology", supra at Unit 4.1; see also, Shastri, et al., supra at 2734 based on estimates of processed peptides isolated from APCs and the number of peptidebound MHC thereon extrapolated from Scatchard plots, the minimum number of peptide/MHC complexes required for T cell stimulation in vivo ranges between 100 and 1000 copies/cell!).
  • tumor-associated antigen mimic-encoding polynucleotides can be identified and constructed for use in cancer immunotherapy according to the in vivo administration method of the invention, or for generation of antibodies for uses such as affinity purification of tumor-associated antigens and mimics.
  • the skin and mucosa will be particularly efficacious sites for administration of naked polynucleotides which encode the antigens of interest for treatment of a particular malignancy. These areas of the body are the sites where most viruses and other antigens that induce CTL responses first encounter the host. Fortuitously, these sites are also those outside of the lymphatic system which tend to contain the highest concentrations of APC's (e.g., approximately 1-2% of the cells in the epidermis are macrophages and dendritic cells).
  • the naked, tumor-associated antigen encoding polynucleotides of the invention will be administered according to medically accepted parameters for cancer immunotherapy; e.g., pertaining to course of treatment and containment of side effects.
  • the method of the invention will be used to stimulate a tumor-associated antigen-specific CTL response against residual tumor cells bearing the antigen after removal of the organ or tissue in which the tumor resided.
  • the method of the invention will be used to stimulate a tumor-associated antigen-specific CTL response against tumor cells in tissues of the host having a relatively high concentration of APCs therein; e.g., skin or mucosa.
  • T lymphocyte tolerance to self-antigens is more effectively broken through co-immunization of the host with self antigens and foreign antigens that resemble self-antigens (see, Mamula, et al., J. Immunol., supra at 1456).
  • the host will preferably be treated with both polynucleotides which encode homologous and heterologous tumor-associated antigens.
  • the host will be co-immunized with protein tumor-associated antigen vaccines (according to medically accepted parameters for cancer immunotherapy) to stimulate assistance by helper T lymphocytes and/or with cytokine-encoding polynucleotides to enhance the performance of the host's immune system (see, e.g., Section I, supra and Caligiuri, et al., J. Clin. Invest., 91:123-132, 1993, infusions of recombinant IL-2 protein to patients with advanced cancers!).
  • protein tumor-associated antigen vaccines according to medically accepted parameters for cancer immunotherapy
  • the preferred practice of the invention will induce CTLs without inducing antibody formation (by avoiding the extracellular release of soluble antigen as discussed above).
  • Example IX antigen-encoding polynucleotides were injected intradermally into mice for expression in APCs according to the invention. As shown in FIGS. 11 and 12, antigen-specific CTLs were detected in sera from the mice after injection, yet no antibodies reactive with the injected antigen were detected. In this respect, it should be noted that the inventors have demonstrated that adminstration of antigens according to the method of the invention selectively boosts production of TH1 lymphocytes in preference to TH2 lymphocytes (see, Examples XI and XII and co-pending U.S. patent application Ser. No. 08/333,068, filed Nov. 1, 1994.). Thus, the method of the invention will stimulate the tumor-associated antigen specific CTL response required for effective cancer immunotherapy without stimulating autoantibody production (i.e., against tumor associated self-antigens in the host).
  • pREVk3 and pRSVIL2 were prepared as follows.
  • a 1040 bp HindllI-Xhol fragment containing the V-J region of this gene was excised and inserted into the polycloning site of the mammalian expression vector pREP7 (Invitrogen, San Diego, Calif.), downstream of the Rous sarcoma virus (RSV) long terminal repeat (LTR) to produce a vector designated pREVk3. Downstream of the rearranged JK1 segment, there is a natural stop codon, which terminates translation.
  • pREP7 Invitrogen, San Diego, Calif.
  • RSV Rous sarcoma virus
  • LTR long terminal repeat
  • pRSVIL-2 an IL-2 expression vector, designated pRSVIL-2
  • the luciferase cDNA in the vector pRSVL was replaced with a 680 bp HindllI-BamHI fragment of pBC12/HIV/IL-2 (American Type Culture Collection, No. 67618) according to the method taught in Cullen, Cell, 46:937, (1986).
  • the Wolff, et al., and Cullen references are incorporated herein to illustrate knowledge in the art concerning construction of these expression vectors.
  • mice with plasmid cDNA Intramuscular injection of mice with plasmid cDNA. Eight week old BALB/c mice were anesthetized with methoxyflurane. Plasmid cDNA (100 ⁇ g per injection) was suspended in 100 ⁇ l of saline, and then was injected four times into the quadricep muscles through a 28-gauge needle at weekly intervals. One group of six mice received 100 ⁇ g of pREVk3. Another group of six mice received 100 ⁇ g each of pREVk3 and pRSVIL-2 while a third group received 100 ⁇ g of saline alone. Just before every injection, blood samples were collected from the orbital arteries.
  • ELISA Enzyme-linked immunosorbent assay
  • the IgM rheumatoid factor Glo is encoded by the Humkv325 gene and has 17.109 idiotype positive kappa light chains.
  • the purified protein was dissolved at 10 ⁇ g/ml in 0.1M borate, 0.2M NaCl, pH 8.2 (i.e., buffered borate saline or BBS), and then 100 ⁇ l aliquots were added to the wells of plastic microtiter plates.
  • BBS/Tween BBS supplemented with 1% bovine serum albumin
  • mice were sacrificed. Muscles into which the genes had been injected were fixed in 10% formalin and processed for histological evaluation.
  • mice were injected with a naked cDNA plasmid intradermally. Gene expression was observed and measured.
  • RNP influenza ribonucleoprotein
  • mice Four eight week old Balb/c mice were injected three times with 15 ⁇ g of pCMV-RNP suspended in 100 ⁇ l of HBSS. Injections were made intradermally at the base of the tails at two week intervals. Cytotoxic T lymphocytes (CTL) recognize antigens presented by class I MHC molecules and play an important role in the elimination of virally infected cells. Intramuscular (i.m.) immunization by means of cDNA expression vectors should be an effective method to introduce antigen into class I MHC molecules and thus stimulate CTL responses.
  • CTL Cytotoxic T lymphocytes
  • Plasmid DNA was purified by CsCI banding in the presence of ethidium bromide and was stored frozen in 10 mM Tris-HCL, 0.1 mM EDTA, pH 8.0. Before injection, the plasmid was precipitated in ethanol and dissolved in normal saline containing 0.1 mM EDTA.
  • the axes of FIG. 2 represent, respectively, the ELISA titer (mean, 1 ounce) against time. Serum dilution for all graph points is 2560.
  • naked polynucleotide encoding for influenza ribonucleoprotein was introduced to Balb/c mice in 3 groups of 6 intranasally.
  • Levels of anti-NP IgG in peripheral blood before and after introduction of the plasmid at various serum dilutions were measured by ELISA as described in Example II. Blood was drawn from each mouse after intranasal introduction after 6 weeks.
  • FIG. 3 graphically depicts the results of the ELISA assays before and after intranasal introduction of the plasmid.
  • the graphs plot ELISA titer against serum dilution.
  • values are shown for individual mice from each group (#1-3) and an average value from all mice in each group (#G1-G3).
  • mice in a second group which received 3 ⁇ 7.5 ⁇ g of plasmid showed enhanced titers of antibody as compared to background (FIG. 3). These data are shown in FIG. 4.
  • mice received the same gravity of plasmid under anesthesia. Expression of RNP as indicated by titers of anti-NP IgG in these mice was substantially similar to the expression achieved in the unanethesized mice. The data for the anethesized mice are shown in FIG. 5.
  • Expression can be enhanced by additional use of absorption promoters, and prolonged by time-released promoters whose identity and use are known in the art such as those suggested in Chien, supra, at Ch. 5.
  • mice Three days after intradermal injection of the tails of naked pCMVlacz into Balb/c mice, the mice were sacrificed. Tissue cultures were obtained at the point of entry for the plasmid and stained for E. coli ⁇ -galactosidase activity. A photograph (40 ⁇ magnification) of a slide from the histological examination of these cultures is contained in FIG. 6.
  • uptake of the plasmid is shown (in blue) to be by mononuclear cells.
  • the fibroblasts in the tissue samples are not stained, thus indicating that the plasmid was not taken up by these cells.
  • the rounded, mononuclear cells which did take up the plasmid appear to be macrophages and/or other antigen presenting cells, which would indicate that uptake of the plasmid is by phagocytosis.
  • FIG. 7 depicts the results of an ELISA performed as described in Example I for serum levels of anti-NP IgG following epidermal administration of pCMVRNP via mechanical means.
  • the plasmid was coated onto the tynes of an uncoated MONO-VACC® device as described supra. (It should be noted that it is alternatively possible for the naked polynucleotides to be lyophilized onto the tynes of the device for longer storage stability).
  • Total plasmid concentration on all of the device tynes was approximately 50 ⁇ g in an isotonic normal saline carrier (approximately 150 ⁇ g plasmid per milliliter).
  • the back of a Balb/c mouse was shaved and the shaved skin gently scratched with the tyne device. As shown in FIG. 7, anti-NP IgG were subsequently detected in serum (e.g., at day 42, the serum from this mouse contained antibodies at a titer of 1:10240).
  • FIG. 8 depicts the results of an ELISA performed as described in Example I for serum levels of anti-NP IgG following epidermal administration of pCMVRNP in conjunction with the application of a chemical agent.
  • the plasmid was suspended in 40 ⁇ g of an isotonic normal saline solution containing approximately 150 ⁇ g of plasmid per milliliter. This solution was absorbed onto the nonadhesive pad of a BAND-AID brand bandage (Johnson & Johnson).
  • a Balb/c mouse was shaved as described in Example V and a commercially available keratinolytic agent (here, the previously described depilatory creme sold under the tradename NAIR) was applied to the shaved skin. After several minutes, the keratinolytic agent was washed off of the skin and the plasmid-containing bandage applied thereto. As shown in FIG. 8, the treated animal developed serum anti-NP IgG at a titer of 1:640.
  • mice were injected intradermally 3 times with 15 ⁇ g of a pCMVRNP plasmid which contained the NP gene from an H1N1 strain of influenza virus (A/PR/8/34; provided by Dr. Inocent N. Mbawvike at the Baylor College of Medicine, U.S.)
  • Control groups included uninjected animals as well as animals injected with an irrelevant plasmid (pnBL3).
  • mice Six weeks after the initial plasmid injections, the animals were challenged with a LD 90 dose of an H3N2 influenza strain (A/HK/68); also provided by Dr. Mbawuike). Intradermally vaccinated mice were significantly protected from the challenge (P(0.01) as compared to unvaccinated control mice; see, FIG. 9 (a Kaplan-Meyer survival curve).
  • pCMVRNP cytomegalovirus immediate early promoter, enhancer and intron region.
  • the other plasmid contained the promoter from the Rous sarcoma virus LTR region (pRSVRNP).
  • pRSVRNP Rous sarcoma virus LTR region
  • mice of the C57/B6 strain were injected intradermally in the tail at two week intervals with 100 ⁇ g naked DNA purified from a CDM8 ova plasmid (described in detail in Shastri, et al., J. Immunol., 150:2724-2736, 1993).
  • the CDM8 ova plasmid contains the full length (1.8 kb) cDNA for ovalbumin.
  • mice 2 weeks after the second gene adminstration, the spleens of the mice were removed and cultured in vitro with lethally irradiated (3000 rad) syngeneic splenocytes that had been pulsed with a synthetic ovalbumin peptide (SIIMFEKL).
  • SIIMFEKL synthetic ovalbumin peptide
  • the cells were incubated with targets of 2 types to test for the generation of cytotoxic T cells by the mice who had received the gene encoding ovalbumin.
  • the targets were mouse EL-4 lymphocytes pulsed with the synthetic ovalbumin peptide, or EL-4 cells that had been stably transfected with the cDNA for ovalbumin (see, FIG. 11; the cDNA for ovalbumin is designated as "EG7" in the FIGURE).
  • the percent lysis of the 2 targets was determined for different effector-to-target ratios (designated as "E:T ratio" in FIG. 11). As shown in FIG.
  • the animals that received the naked CDM8 ova plasmid had produced cytotoxic T cells that were specific for the ovalbumin targets (i.e., for EL-4 with the ovalbumin peptide and for EG7), but were not specific for the control EL-4 cells (i.e., those without the ovalbumin peptide).
  • C57/B6 mice vaccinated intradermally with CDM8 ova plasmids were also screened for antibodies to ovalbumin.
  • Sera collected 6 weeks after administration of the CDM8 ova plasmids did not contain any detectable levels of antibody (as measured using an enzyme-linked immunoabsorbent assay on microtiter plates coated with ovalbumin; see, FIG. 12).
  • IM intramuscularly
  • ID intradermally
  • PR ⁇ g ⁇ -galactosidase protein
  • Serum samples were serially diluted in BBS starting at a 1:40 dilution for the first 8 weeks, them a 1:320 dilution thereafter. These samples were added to the plates and stored overnight at room temperature. Plates were washed in BBS+0.05% polysorbate 20, then reacted with a 1:2000 dilution of alkaline phosphatase labeled goat anti-mouse IgG antibody (Jackson Immunoresearch Labs., West Grove, Pa.) for 1 hour at room temperature, or were reacted with a 1:2000 dilution of alkaline phosphatase labeled goat anti-mouse IgG 1 antibody (Southern Biotech of AL), or were reacted with a 1:500 dilution of alkaline phosphatase labled rat anti-mouse IgG 2A antibody (Pharmingen, of CA), under the same conditions.
  • antibody responses of equivalent magnitude were induced in the animals who had received the pCMV Lac-Z plasmids by ID injection and the animals who had received the PR, while lesser antibody responses were measured in the animals who had received the pCMV Lac-Z plasmids by IM injection.
  • the animals were then boosted with 0.5 ⁇ g of PR at a separate site by ID injection. If these animals had developed memory T cells to control production of antibody to ⁇ -galactosidase, they would be expected to mount a more vigorous immune response after boosting with soluble protein antigen than had been demonstrated in response to the priming dose of antigen.
  • IgG 2A antibodies are serological markers for a TH1 type immune response, whereas IgG 1 antibodies are indicative of a TH2 type immune response.
  • TH2 responses include the allergy-associated IgE antibody class; soluble protein antigens tend to stimulate relatively strong TH2 responses.
  • TH1 responses are induced by antigen binding to macrophages and dendritic cells. TH1 responses are to be of particular importance in the treatment of allergies and AIDS.
  • mice were vaccinated with pCMV Lac-Z or protein as described in the preceding example.
  • any IgG 2a and IgG 1 to ⁇ -galactosidase were measured by enzyme-linked immunoabsorbent assay (using antibodies specific for the IgG 1 and IgG 2A subclasses) on microtiter plates coated with the enzyme.
  • mice who received the plasmid by ID injection produced high titers of IgG 2A antibodies.
  • immunization of the mice with the enzyme itself (“PR") induced production of relatively high titers of IgG 1 antibodies.
  • PR enzyme itself
  • low titers of both IgG 2A and IgG 1 antibodies were produced without apparent selectivity.
  • the data shown in the FIGURES comprise averages of the values obtained from each group of 4 mice.
  • Example XI The experiments described in Example XI were repeated in separate groups of mice, except that (1) only a priming dose was tested, and (2) the pCMV Lac-Z plasmid was administered to one group of 4 mice using the tyne device described in Example V, while ⁇ -galactosidase protein (10 ⁇ g) was administered to another group of 4 mice by intradermal (ID) injection.
  • mice who received plasmid produced relatively low titers of IgG 1 antibody compared to the mice who received the protein.
  • the mice who received plasmid produced substantially higher titers of IgG 2A antibody as compared to the mice who received the protein.
  • mice who received the plasmid via scratching of their skin with the tyne device produced even higher titers of IgG 2A antibody than did the mice who received the same plasmid via ID injection (both of which groups produced higher titers of IgG 2A antibody than did the mice who received the plasmid via IM injection).
  • scratching of skin with the tyne device attracts greater number of APC's to the "injured" point of entry for the naked polynucleotides and are consistent with the theory that APC's are more efficient targets for gene administration and expression than are muscle or other somatic cells.
  • the data shown in the FIGURES comprise averages of the values obtained from each group of 4 mice.
  • TH1 responses e.g., INF Y secretion
  • levels of IL-2 indicator of a TH2 responses
  • INF Y were assayed in the sera of the plasmid and protein injected mice of Example XI, after one booster injection of antigen.
  • IL-2 levels were assayed as described in Example I;
  • INF Y levels were assayed with an anti-INF Y murine antibody assay (see, e.g., Coligan, "Current Protocols in Immunology", Unit 6.9.5., Vol. 1, Wiley & Sons, 1994).
  • levels of IL-4 in the protein injected mice were substantially higher than in plasmid injected mice (by about a 9:1 ratio).
  • levels of INF y in the plasmid injected mice were substantially higher than in the protein injected mice (by a ratio of about 11:1).
  • mice were immunized as described in Example V, except that they received pCMV-NP (described in Example I) rather than ovalbumin DNA.
  • Control mice received pCMV-BL (a plasmid with a non-encoding insert).
  • the total amount of pDNA loaded on the tyne device per inoculation was 50 ⁇ g of pCMV-NP and 25 ⁇ g of pCMV-BL.
  • mice 36 weeks after immunization, the mice were sacrificed and splenocytes were removed for use in standard mixed lymphocyte cultures.
  • the cultures were grown in the presence of a known synthetic peptide representing the major H-2 d restricted CTL epitope of the NP protein.
  • the cultures were assayed for anti-NP CTL activity 5-6 days later using NP peptide pulsed syngeneic P815 tumor cells (ATCC #TIB64, Rockville, Md.) as targets.
  • mixed lymphocyte cultures prepared from the pCMV-NP injected animals displayed high levels of specific anti-NP cytolytic activity, reaching 10%, 30% and 80% of specific lysis at an effector to target (E/T) ratio of 5:1, 15:1 and 45:1, respectively.
  • Control mice only displayed 1%, 1% and 9% under the same conditions.
  • CTL activity in absense of exposure to the H-2 d epitope peptide, there were not significant differences in CTL activity in the pCMV-NP injected and control mice (FIG. 25). These data indicate selective activation of TH1 cells in the pCMV-NP injected mice.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
US08/334,260 1993-08-26 1994-11-03 Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides Expired - Fee Related US5679647A (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US08/334,260 US5679647A (en) 1993-08-26 1994-11-03 Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
PCT/US1995/014097 WO1996014074A1 (fr) 1994-11-03 1995-11-01 Procedes et dispositifs destines a immuniser un hote d'antigenes associes a une tumeur par l'administration de polynucleotides nus codant des peptides antigeniques associes a une tumeur
AT95940581T ATE323496T1 (de) 1994-11-03 1995-11-01 Verwendung von nackten polynukleotiden zur herstellung eines medikaments für die behandlung von tumoren
CA002203991A CA2203991C (fr) 1994-11-03 1995-11-01 Procedes et dispositifs destines a immuniser un hote d'antigenes associes a une tumeur par l'administration de polynucleotides nus codant des peptides antigeniques associes a une tumeur
EP95940581A EP0789574B1 (fr) 1994-11-03 1995-11-01 Utilisation des polynucléotides nus dans la fabrication d'un médicament pour le traitement des tumeurs
AU41981/96A AU4198196A (en) 1994-11-03 1995-11-01 Methods and devices for immunizing a host to tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
DE69534946T DE69534946T2 (de) 1994-11-03 1995-11-01 Verwendung von nackten Polynukleotiden zur Herstellung eines Medikaments für die Behandlung von Tumoren
JP8515385A JPH10509702A (ja) 1994-11-03 1995-11-01 腫瘍関連抗原ペプチドをコードする裸のポリヌクレオチドの投与によって腫瘍関連抗原に対して宿主を免疫する方法及び装置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11244093A 1993-08-26 1993-08-26
PCT/US1994/009661 WO1995005853A1 (fr) 1993-08-26 1994-08-25 Procede, compositions et dispositifs pour l'administration de polynucleotides nus qui codent des peptides a activite biologique
US08/334,260 US5679647A (en) 1993-08-26 1994-11-03 Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11244093A Continuation-In-Part 1993-08-26 1993-08-26

Publications (1)

Publication Number Publication Date
US5679647A true US5679647A (en) 1997-10-21

Family

ID=23306377

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/334,260 Expired - Fee Related US5679647A (en) 1993-08-26 1994-11-03 Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides

Country Status (8)

Country Link
US (1) US5679647A (fr)
EP (1) EP0789574B1 (fr)
JP (1) JPH10509702A (fr)
AT (1) ATE323496T1 (fr)
AU (1) AU4198196A (fr)
CA (1) CA2203991C (fr)
DE (1) DE69534946T2 (fr)
WO (1) WO1996014074A1 (fr)

Cited By (267)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008713A1 (fr) * 1997-08-13 1999-02-25 The Uab Research Foundation Vaccination par application topique de vecteurs genetiques
WO1999041366A1 (fr) * 1998-02-12 1999-08-19 The Board Of Trustees Of The Leland Stanford Junior University Introduction d'acide nucleique dans des cellules cutanees, par application topique
WO1999046988A1 (fr) * 1998-03-20 1999-09-23 Genzyme Corporation Compositions et methodes de vaccination specifique de l'antigene
WO1999051748A2 (fr) 1998-04-07 1999-10-14 Corixa Corporation Proteines hybrides d'antigenes de mycobacterium tuberculosis et leurs utilisations
WO1999058658A2 (fr) 1998-05-13 1999-11-18 Epimmune, Inc. Vecteurs d'expression destines a stimuler une reponse immunitaire et procedes de leur utilisation
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
WO2000025813A1 (fr) * 1998-10-29 2000-05-11 Dana-Farber Cancer Institute IMMUNOTHERAPIE ET DIAGNOSTIC DU CANCER AU MOYEN D'ANTIGENES UNIVERSELS ASSOCIES A DES TUMEURS TELS QUE hTERT
WO2000066179A1 (fr) * 1999-05-03 2000-11-09 The Uab Research Foundation Immunisation genetique non invasive, produits d'expression obtenus a partir de celle-ci et utilisations
WO2000067761A1 (fr) * 1999-05-06 2000-11-16 Wake Forest University Compositions et procedes d'identification d'antigenes provoquant une reponse immunitaire
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
WO2001089622A1 (fr) 2000-05-22 2001-11-29 Becton, Dickinson And Company Applicateur dote d'une surface abrasive recouverte d'une substance devant etre appliquee sur la peau
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US20020007173A1 (en) * 1997-07-10 2002-01-17 Kundig Thomas M. Method of inducing a CTL response
US6348449B1 (en) * 1993-09-21 2002-02-19 The Trustees Of The University Of Pennsylvania Methods of inducing mucosal immunity
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US6359054B1 (en) 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US6432641B1 (en) 1997-12-16 2002-08-13 University Of Saskatchewan Technologies Inc. Conductive metal-containing nucleic acids
US20020142337A1 (en) * 2001-03-29 2002-10-03 Edwards David N. Hybrid gene libraries and uses thereof
US20020151515A1 (en) * 1999-06-18 2002-10-17 Roberts Bruce L. Preparation and use of superior vaccines
US20020155093A1 (en) * 1997-02-18 2002-10-24 Houghton Alan N. Method for stimulation of an immune response to a differentiation antigen stimulated by an altered antigen
US20020175317A1 (en) * 2001-05-24 2002-11-28 Lee Jeremy Stuart Nucleic acid circuit elements and methods
US20020188245A1 (en) * 2001-06-08 2002-12-12 Martin Frank E. Device for manipulating a needle or abrader array and method of use
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
US20030028000A1 (en) * 2000-10-31 2003-02-06 Nazneen Aziz CYP1B1 nucleic acids and methods of use
WO2003015615A2 (fr) 2001-08-15 2003-02-27 Brown University Research Foundation Traitement de dystrophies musculaires et de troubles connexes
US6528315B2 (en) 1997-06-30 2003-03-04 Aventis Pharma S.A. Method for transferring nucleic acid into multicelled eukaryotic organism cells and combination therefor
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US20030072764A1 (en) * 2001-04-05 2003-04-17 O'hagan Derek Mucosal boosting following parenteral priming
US20030087848A1 (en) * 2000-02-03 2003-05-08 Bratzler Robert L. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20030093040A1 (en) * 2001-10-29 2003-05-15 Mikszta John A. Method and device for the delivery of a substance
US20030109478A1 (en) * 2000-03-03 2003-06-12 Valentis, Inc. Nucleic acid formulations for gene delivery and methods of use
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
WO2003070920A1 (fr) * 2002-01-18 2003-08-28 The Uab Research Foundation Vaccination, administration de vaccins et de medicaments par application topique de vecteurs et de vecteurs recombinants d'extraits de vecteurs, immunisation genetique non invasive, produits d'expression issus de ces elements et leurs utilisations
US20030176398A1 (en) * 2001-06-11 2003-09-18 Gallop Mark A. Prodrugs of GABA analogs, compositions and uses thereof
US20030180949A1 (en) * 2000-11-16 2003-09-25 John Levy Avoidance of undesirable replication intermediates in plasmid propagation
US6635624B1 (en) 1993-10-22 2003-10-21 Institut Pasteur Nucleotide vector composition containing such vector and vaccine for immunization against hepatitis
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6653292B1 (en) 1994-07-15 2003-11-25 University Of Iowa Research Foundation Method of treating cancer using immunostimulatory oligonucleotides
US6656700B2 (en) 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
US20030224392A1 (en) * 2002-01-28 2003-12-04 Manuel Engelhorn Method for identification of mutant antigens with enhanced immunogenicity
US20030224485A1 (en) * 2002-05-06 2003-12-04 Molday Robert S. Expression system for ABC transporters
US20030228634A1 (en) * 2001-11-07 2003-12-11 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens and methods for their design
US6686188B2 (en) 2000-05-26 2004-02-03 Amersham Plc Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20040033234A1 (en) * 2000-05-10 2004-02-19 Neil Berinstein Immunogenic polypetides encoded by mage minigenes and uses thereof
US20040033237A1 (en) * 2000-04-28 2004-02-19 Genoveffa Franchini Immunogenicity using a combination of dna and vaccinia virus vector vaccines
WO2004019777A2 (fr) 2002-08-29 2004-03-11 Becton Dickinson And Company Administration d'une substance par l'intermediaire d'une surface micro-abrasive rotative
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US20040087534A1 (en) * 1994-07-15 2004-05-06 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
WO2004050828A2 (fr) 2002-11-27 2004-06-17 Agensys, Inc. Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20040223949A1 (en) * 2002-10-22 2004-11-11 Sunnybrook And Women's College Health Sciences Center Aventis Pasteur, Ltd. Vaccines using high-dose cytokines
US20040235019A1 (en) * 2003-03-06 2004-11-25 Agouron Pharmaceuticals, Inc. Diagnostics and therapeutics for the gene expression signature of PPAR-gamma receptor ligand
US20040244742A1 (en) * 2003-06-05 2004-12-09 Caterpillar Inc. Control system and method for engine valve actuator
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US6835184B1 (en) 1999-09-24 2004-12-28 Becton, Dickinson And Company Method and device for abrading skin
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US20050054601A1 (en) * 1997-01-23 2005-03-10 Coley Pharmaceutical Gmbh Pharmaceutical composition comprising a polynucleotide and optionally an antigen especially for vaccination
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US20050118186A1 (en) * 2003-06-17 2005-06-02 Chih-Sheng Chiang Combinations of tumor-associated antigens in compositions for various types of cancers
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
US20050181458A1 (en) * 2003-09-05 2005-08-18 Fiona Harding HPV CD8+ T-cell epitopes
US6939862B2 (en) 1997-06-30 2005-09-06 Aventis Pharma S.A. Method for transferring nucleic acid into striated muscles
US6942862B2 (en) * 1996-04-01 2005-09-13 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
US6951845B2 (en) * 1993-08-26 2005-10-04 The Regents Of The University Of California Method for treating allergic lung disease
US20050256045A1 (en) * 2004-05-13 2005-11-17 Mahmoud Ameri Apparatus and method for transdermal delivery of parathyroid hormone agents
WO2005118864A2 (fr) 2004-05-28 2005-12-15 Agensys, Inc. Anticorps et molecules apparentees qui se lient aux proteines d'antigene des cellules souches de prostate (proteines de psca)
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
WO2006031391A2 (fr) 2004-08-25 2006-03-23 Becton, Dickinson And Company Procede et dispositif pour l'administration d'une substance comportant un couvercle
US20060089326A1 (en) * 1994-07-15 2006-04-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20060094006A1 (en) * 2002-05-01 2006-05-04 Genoveffa Franchini Immunotherapy regimens in hiv-infected patients
US20060110790A1 (en) * 2002-05-06 2006-05-25 Robert Molday Expression system for large functional proteins
US20060116342A1 (en) * 1999-10-07 2006-06-01 Cornell Research Foundation, Inc. Protective immunity or immunological tolerance induced with RNA, particularly total cellular RNA
WO2006071983A2 (fr) 2004-12-29 2006-07-06 Mannkind Corporation Combinaisons d'antigenes associes a une tumeur dans des compositions pour differents types de cancers
US20060153844A1 (en) * 2004-12-29 2006-07-13 Thomas Kundig Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060165711A1 (en) * 2004-12-29 2006-07-27 Bot Adrian I Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
WO2006086454A2 (fr) 2005-02-08 2006-08-17 President And Fellows Of Harvard College Procedes et compositions pour l'extension de la duree de vie et l'augmentation de la resistance au stress des cellules et des organismes
WO2006093030A1 (fr) 2005-02-28 2006-09-08 Oncotherapy Science, Inc. Peptides epitopes derives d’un recepteur de facteur de croissance endotheliale vasculaire 1 et vaccins contenant ces peptides
US20060233761A1 (en) * 2005-02-23 2006-10-19 Arnold John J Alkyl-glycoside enhanced vaccination
US20060247190A1 (en) * 2002-10-21 2006-11-02 Kathleen Beach Compositions and methods for treating human papillomavirus mediated disease
US7160869B2 (en) 1998-12-16 2007-01-09 University Of Saskatchewan Biologically active metal-containing nucleic acids
US20070015282A1 (en) * 1995-09-15 2007-01-18 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
WO2007013576A1 (fr) 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Gene tom34 lie au cancer du colon
US20070037151A1 (en) * 2003-04-28 2007-02-15 Babe Lilia M Cd4+ human papillomavirus (hpv) epitopes
US20070036807A1 (en) * 2005-03-04 2007-02-15 Tuck Stephen F Compositions comprising structurally stable conjugate molecules
US20070092517A1 (en) * 2005-08-10 2007-04-26 Oklahoma Medical Research Foundation Truncated memapsin 2 compositions and treatments
US20070190073A1 (en) * 1999-11-15 2007-08-16 Stephen Tuck Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US20070224210A1 (en) * 2002-08-19 2007-09-27 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids
EP1842549A2 (fr) 1999-12-28 2007-10-10 Pharmexa Inc. Minigènes optimisés et peptides encodées associées
US20070269464A1 (en) * 2000-04-28 2007-11-22 Simard John J Epitope synchronization in antigen presenting cells
US20080021196A1 (en) * 1999-06-28 2008-01-24 The Board Of Trustees Of The University Of Illinois Inhibitors of memapsin 2 and use thereof
EP1903056A2 (fr) 2002-12-10 2008-03-26 Idm Pharma, Inc. Peptides d'antigènes HLA-A1, -A2 -A3, -A24, -B7 et -B44 associés aux tumeurs et compositions
EP1911461A2 (fr) 2000-10-19 2008-04-16 Pharmexa Inc. Peptides de liaisons HLA de classe I et II et leurs utilisations
US20080131453A1 (en) * 2003-08-12 2008-06-05 Medical College Of Georgia Research Institute Campylobacter Jejuni Outer Membrane Protein Immunogenic Composition
WO2008102557A1 (fr) 2007-02-21 2008-08-28 Oncotherapy Science, Inc. Vaccins peptidiques pour les cancers exprimant des antigènes associés à une tumeur
WO2008109953A1 (fr) * 2007-03-14 2008-09-18 Sai Ying Ko Procédé de traitement du cancer par l'administration mucosale d'interleukine
US20080254059A1 (en) * 2005-02-11 2008-10-16 Bett Andrew J Adenovirus Serotype 26 Vectors, Nucleic Acid and Viruses Produced Thereby
WO2008126413A1 (fr) 2007-04-11 2008-10-23 Oncotherapy Science, Inc. Peptides tem8 et vaccins les comprenant
US20080294116A1 (en) * 2005-11-18 2008-11-27 Wolter James T Coatable Compositions, Coatings Derived Therefrom and Microarrays Having Such Coatings
US20080319404A1 (en) * 2005-12-21 2008-12-25 Pekurovsky Mikhail L Microneedle Devices
US7488490B2 (en) 1997-03-10 2009-02-10 University Of Iowa Research Foundation Method of inducing an antigen-specific immune response by administering a synergistic combination of adjuvants comprising unmethylated CpG-containing nucleic acids and a non-nucleic acid adjuvant
EP2022797A2 (fr) 2000-08-28 2009-02-11 Agensys, Inc. Acide nucléique et protéine correspondante intitulée 85P1B3 utile dans le traitement et la détection du cancer
US20090042202A1 (en) * 2000-12-04 2009-02-12 Institute For Systems Biology Prostate-specific polypeptide pamp and encoding nucleic acid molecules
US7524828B2 (en) 1994-07-15 2009-04-28 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO2009059011A2 (fr) 2007-11-01 2009-05-07 Mayo Foundation For Medical Education And Research Peptides de liaison hla-dr et leurs utilisations
WO2009058564A2 (fr) 2007-11-01 2009-05-07 Maxygen, Inc. Polypeptide immunosuppresseur et acides nucléiques
US7534772B2 (en) 2000-06-22 2009-05-19 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
US20090130674A1 (en) * 1995-09-15 2009-05-21 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
EP2070949A2 (fr) 2002-06-10 2009-06-17 Vaccinex, Inc. Gène s'exprimant par action différentielle dans le cancer du sein et de la vessie, et polypeptides codés
EP2075582A2 (fr) 2000-07-12 2009-07-01 Agensys, Inc. Nouvel antigène de tumeur utile dans le diagnostic et la thérapie des cancers de la vessie, ovaire, poumon et rein
US20090275504A1 (en) * 2008-05-05 2009-11-05 Janice Mayne Pcsk9 proteins, fragments thereof and methods of modulating pcsk9 phosphorylation and low density lipoprotein (ldlr) degradation
WO2010023877A1 (fr) 2008-08-27 2010-03-04 Oncotherapy Science, Inc. Prmt1 pour gènes cibles du traitement et du diagnostic du cancer
EP2177534A2 (fr) 1999-11-18 2010-04-21 Pharmexa Inc. Analogues hétéroclites de classe 1 épitopes
WO2010065613A2 (fr) 2008-12-03 2010-06-10 The Johns Hopkins University Annexina2 en tant que cible immunologique
US7741300B2 (en) 1998-06-25 2010-06-22 National Jewish Medical And Research Center Methods of using nucleic acid vector-lipid complexes
US7744925B2 (en) 1994-12-02 2010-06-29 Quadrant Drug Delivery Limited Solid dose delivery vehicle and methods of making same
WO2010080985A1 (fr) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions et procédés pour induire la différenciation du tissu adipeux brun
WO2010083203A2 (fr) 2009-01-13 2010-07-22 StemBios Technologies, Inc. Cellules souches non embryonnaires et leurs utilisations
US7763589B2 (en) 1996-09-17 2010-07-27 Novartis Vaccines And Diagnostics, Inc. Compositions and methods for treating intracellular diseases
WO2010086294A2 (fr) 2009-01-28 2010-08-05 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations
EP2218730A1 (fr) 1997-11-28 2010-08-18 Merck Serono Biodevelopment Séquence génomique de Chlamydia pneumoniae, polypeptides, fragments et leurs utilisations, en particulier pour le diagnostic, la prévention et le traitement de l'infection
WO2010095428A1 (fr) 2009-02-18 2010-08-26 Oncotherapy Science, Inc. Peptides foxm1 et vaccins contenant ceux-ci
WO2010106770A1 (fr) 2009-03-18 2010-09-23 Oncotherapy Science, Inc. Peptides neil3 et vaccins les comprenant
WO2010124365A1 (fr) 2009-04-27 2010-11-04 Ottawa Hospital Research Institute Compositions et méthodes permettant de moduler les cellules souches et leurs utilisations
WO2010137295A1 (fr) 2009-05-26 2010-12-02 Oncotherapy Science, Inc. Peptides cdc45l et vaccins comprenant ceux-ci
US20100305197A1 (en) * 2009-02-05 2010-12-02 Massachusetts Institute Of Technology Conditionally Active Ribozymes And Uses Thereof
EP2280030A2 (fr) 2001-04-10 2011-02-02 Agensys, Inc. Acides nucléiques et protéines correspondantes utiles dans la détection et le traitement des différents cancers
EP2287186A1 (fr) 2001-09-06 2011-02-23 Agensys, Inc. Acide nucléique et protéine corréspondante designés par STEAP-1 utiles dans le traitement et la détection du cancer
EP2302041A1 (fr) 2001-11-07 2011-03-30 Agensys, Inc. Acide nucléique et protéine correspondante intitulée 161P2F10B utile pour le traitement et la détection du cancer
EP2301954A2 (fr) 2002-08-16 2011-03-30 Agensys, Inc. Acides nucléiques et protéines correspondantes 282G1G3 utilisées dans le traitement et la détection du cancer
EP2311863A1 (fr) 2001-03-05 2011-04-20 Agensys, Inc. Acide nucléique et protéine correspondante 121P1F1 utilisés dans le traitement et la détection du cancer
EP2319524A1 (fr) 2003-05-30 2011-05-11 Agensys, Inc. Variantes de l'antigène de cellules souches de la prostate (PSCA) et sous-séquences de celles-ci
EP2325305A1 (fr) 2005-02-25 2011-05-25 Oncotherapy Science, Inc. Vaccins à base de peptides pour cancers du poumon exprimant des polypeptides TTK, URLC10 ou KOC1
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
WO2011074236A1 (fr) 2009-12-14 2011-06-23 Oncotherapy Science, Inc. Peptides tmem22 et vaccins les comprenant
EP2343315A2 (fr) 2003-02-10 2011-07-13 Agensys, Inc. Acide nucléique et protéine correspondante appelée 158P1D7 utile pour le traitement et la détection de cancer de la vessie et autres
US7999088B2 (en) 2005-06-17 2011-08-16 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
US20110200631A1 (en) * 2008-10-23 2011-08-18 Morsey Mohamad A Lawsonia intracellularis vaccines
WO2011106705A2 (fr) 2010-02-26 2011-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Protocoles de vaccination adn/protéine
WO2011111392A1 (fr) 2010-03-11 2011-09-15 Oncotherapy Science, Inc. Peptides hjurp et vaccins les comprenant
EP2366711A2 (fr) 2001-03-14 2011-09-21 Agensys, Inc. Acide nucléique et protéine correspondante 125P5C8 utilisés dans le traitement et la détection du cancer
EP2368575A2 (fr) 1999-04-08 2011-09-28 Intercell USA, Inc. Formulation seche pour immunisation transcutanee
WO2011122022A1 (fr) 2010-04-02 2011-10-06 Oncotherapy Science, Inc. Peptides d'ect2 et vaccins les comprenant
WO2012019002A2 (fr) 2010-08-04 2012-02-09 StemBios Technologies, Inc. Cellules souches somatiques
WO2012041867A2 (fr) 2010-09-27 2012-04-05 China Agricultural University Vaccin polyvalent comprenant un antigène et un adn destiné à prévenir et à traiter des maladies autoimmunes
EP2444099A1 (fr) 2005-03-31 2012-04-25 Agensys, Inc. Anticorps et molécules correspondantes se liant aux protéines 161P2F10B
WO2012068463A2 (fr) 2010-11-18 2012-05-24 Beth Israel Deaconess Medicall Center, Inc. Méthodes de traitement de l'obésité par inhibition de la nicotinamide n-méthyltransférase (nnmt)
WO2012071513A2 (fr) 2010-11-24 2012-05-31 Hong Gao Expansion de cellules souches hématopoïétiques
EP2476699A2 (fr) 2006-10-17 2012-07-18 Oncotherapy Science, Inc. Vaccins de peptide pour cancers exprimant les polypeptides MPHOSPH1 ou DEPDC1
WO2013018690A1 (fr) 2011-07-29 2013-02-07 国立大学法人徳島大学 Peptide issu de erap1 et son utilisation
WO2013024582A1 (fr) 2011-08-12 2013-02-21 Oncotherapy Science, Inc. Peptides mphosph1 et vaccins les contenant
WO2013039996A1 (fr) 2011-09-13 2013-03-21 Dana-Farber Cancer Institute, Inc. Compositions et procédés pour induction et activité de tissu adipeux brun à l'aide de fndc5
WO2013040341A2 (fr) 2011-09-16 2013-03-21 Ottawa Hospital Research Institute Compositions wnt7a et leurs procédés d'utilisation
WO2013049459A2 (fr) 2011-09-28 2013-04-04 StemBios Technologies, Inc. Cellules souches somatiques
WO2013055911A1 (fr) 2011-10-14 2013-04-18 Dana-Farber Cancer Institute, Inc. Biomarqueur znf365/zfp365 pouvant prévoir une réponse anticancéreuse
WO2013116965A1 (fr) 2012-02-10 2013-08-15 Beijing Advaccine Biotechnology Co. Ltd Vaccin associant un antigène et un adn pour la prévention et le traitement d'une infection par un vrs
US8574599B1 (en) 1998-05-22 2013-11-05 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
WO2014010231A1 (fr) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Peptides épitopes du kif20a pour cellules th1 et vaccins les contenant
WO2014010232A1 (fr) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Peptides épitopes du ly6k pour cellules th1 et vaccins les contenant
WO2014041784A1 (fr) 2012-09-11 2014-03-20 Oncotherapy Science, Inc. Peptides ube2t et vaccins les contenant
WO2014044690A1 (fr) 2012-09-18 2014-03-27 Valneva Austria Gmbh Vaccins améliorés
WO2014093897A1 (fr) 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Vaccin contre wt1
WO2014141683A1 (fr) 2013-03-12 2014-09-18 Oncotherapy Science, Inc. Peptides kntc2 et vaccins les contenant
US8911742B2 (en) 1996-11-14 2014-12-16 The United States Of America As Represented By The Secretary Of The Army Transcutaneous immunization without heterologous adjuvant
EP2816107A1 (fr) 2013-06-17 2014-12-24 Hong Gao Procédé d'expansion de cellules souches hématopoïétiques
US8961477B2 (en) 2003-08-25 2015-02-24 3M Innovative Properties Company Delivery of immune response modifier compounds
WO2015054012A1 (fr) 2013-10-07 2015-04-16 The Trustees Of The University Of Pennsylvania Vaccins ayant pour adjuvant l'interleukine-33
WO2015081155A1 (fr) 2013-11-29 2015-06-04 The Trustees Of The University Of Pennsylvania Vaccin à base de mers-cov
WO2015164743A2 (fr) 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Suppresseur de tumeur et biomarqueurs oncogènes prédictifs de réponse à un inhibiteur de point de contrôle anti-immunitaire
US9175310B2 (en) 2011-03-21 2015-11-03 Altimmune Inc Rapid and prolonged immunologic-therapeutic
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
WO2016054003A1 (fr) 2014-10-01 2016-04-07 The Trustees Of The University Of Pennsylvania Vaccins possédant un antigène et une interleukine-21 en tant qu'adjuvant
WO2016057367A1 (fr) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Biomarqueurs à base d'angiopoïétine -2 utilisés pour la prédiction de la réponse de point de contrôle anti-immunitaire
WO2016057651A1 (fr) 2014-10-09 2016-04-14 Dana-Farber Cancer Institute, Inc. Schéma posologique d'il-2 variables multiples pour le traitement de troubles immunitaires
EP3026432A2 (fr) 2010-12-27 2016-06-01 Brown University Procédé de prévision de la réponse du patient au traitement avec biglycan
WO2016123285A1 (fr) 2015-01-29 2016-08-04 The Trustees Of The University Of Pennsylvania Associations d'inhibiteurs de point de contrôle immunitaires et de vaccins, et leur utilisation en immunothérapie
US9416371B2 (en) 2008-10-31 2016-08-16 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
WO2016144673A1 (fr) 2015-03-06 2016-09-15 Dana-Farber Cancer Institute, Inc. Biomarqueurs pd-l2 prédictifs de réponses d'inhibiteurs de la voie pd-1 dans les cancers oesophagogastriques
US9463227B2 (en) 2011-03-11 2016-10-11 Advaxis, Inc. Listeria-based adjuvants
WO2016183420A1 (fr) 2015-05-13 2016-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Procédés et compositions pour induire une réponse immunitaire à l'aide de constructions d'éléments conservés
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
WO2017024182A1 (fr) 2015-08-04 2017-02-09 Duke University Polymères discrets intrinsèquement désordonnés codés génétiquement pour administration et leurs procédés d'utilisation
US9592303B2 (en) 2013-05-30 2017-03-14 Duke University Enzyme-catalyzed synthesis of site-specific and stoichiometric biomolecule-polymer conjugates
WO2017066561A2 (fr) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Modulation de pd-1 des lymphocytes t régulateurs pour réguler les réponses immunitaires effectrices des lymphocytes t
WO2017075329A2 (fr) 2015-10-29 2017-05-04 Dana-Farber Cancer Institute, Inc. Procédés pour identifier, évaluer, prévenir et traiter des troubles métaboliques au moyen de pm20d1 et d'acides aminés n-lipidés
US9644212B2 (en) 2008-05-19 2017-05-09 Advaxis, Inc. Dual delivery system for heterologous antigens
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
WO2017112825A2 (fr) 2015-12-21 2017-06-29 Duke University Conjugués polymères ayant une antigénicité réduite et leurs procédés d'utilisation
EP3219720A2 (fr) 2008-12-05 2017-09-20 Onco Therapy Science, Inc. Peptides à épitope wdrpuh et vaccins les contenant
WO2017165412A2 (fr) 2016-03-21 2017-09-28 Dana-Farber Cancer Institute, Inc. Régulateurs de l'expression génique spécifiques à l'état d'épuisement des lymphocytes t et leurs utilisations
WO2017190147A1 (fr) 2016-04-29 2017-11-02 Inovio Pharmaceuticals, Inc. Utilisation in vivo de chondroïtinase et/ou d'hyaluronidase pour améliorer l'administration d'un agent
US9873722B2 (en) 2011-09-16 2018-01-23 Fate Therapeutics, Inc. Wnt compositions and therapeutic uses of such compositions
EP3296317A1 (fr) 2011-10-28 2018-03-21 OncoTherapy Science, Inc. Peptides topk et vaccins les comportant
WO2018057618A1 (fr) 2016-09-20 2018-03-29 Dana-Farber Cancer Institute, Inc. Compositions et méthodes pour l'identification, l'évaluation, la prévention et le traitement de la lma au moyen de biomarqueurs usp10 et de modulateurs
WO2018094106A2 (fr) 2016-11-16 2018-05-24 University Of South Florida Antagonistes allostériques de gprc6a et leur utilisation dans l'atténuation de protéinopathies
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
WO2018129039A1 (fr) 2017-01-04 2018-07-12 President And Fellows Of Harvard College Modulation du domaine d'homologie nudix (nhd) au moyen d'analogues de mononucléotide de nicotinamide et leurs dérivés
US10022441B2 (en) 2013-03-27 2018-07-17 Immunovaccine Technologies, Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
US10058599B2 (en) 2012-03-12 2018-08-28 Advaxis, Inc. Suppressor cell function inhibition following Listeria vaccine treatment
US10064898B2 (en) 2011-03-11 2018-09-04 Advaxis, Inc. Listeria-based adjuvants
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
US10272052B2 (en) 2017-02-24 2019-04-30 University Of South Florida Compositions and methods for the treatment of tauopathies
WO2019144047A1 (fr) 2018-01-18 2019-07-25 University Of South Florida Cellules dendritiques hétérogènes immatures mortes stimulées par un antigène en tant qu'agents thérapeutiques de maladies
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10370664B2 (en) 2013-11-07 2019-08-06 University Of Southern California Use of IKK epsilon inhibitors to activate NFAT and T cell response
US10376495B2 (en) 2016-11-23 2019-08-13 University Of South Florida Small molecules that mimic or antagonize actions of granulocyte colony-stimulating-factor (G-CSF)
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
WO2019165372A1 (fr) 2018-02-26 2019-08-29 President And Fellows Of Harvard College Compositions de modulateurs et/ou de mutants de parp14 et leur utilisation thérapeutique
WO2019199673A1 (fr) 2018-04-09 2019-10-17 President And Fellows Of Harvard College Modulateurs de récepteurs nucléaires et leurs procédés d'utilisation
US10533033B2 (en) 2015-01-06 2020-01-14 Immunovaccine Technologies Inc. Lipid A mimics, methods of preparation, and uses thereof
US10538553B2 (en) 2018-01-05 2020-01-21 University Of South Florida Compounds for the treatment of neurodegenerative diseases
WO2020027239A1 (fr) 2018-08-02 2020-02-06 オンコセラピー・サイエンス株式会社 Peptide dérivé de cdca1 et vaccin le contenant
WO2020111167A1 (fr) 2018-11-30 2020-06-04 国立大学法人徳島大学 Agent thérapeutique pour le traitement du cancer du sein comprenant un peptide inhibiteur d'interaction big3-phb2 dérivé de phb2
US10675283B2 (en) 2017-03-24 2020-06-09 University Of South Florida Compositions and methods for white to beige adipogenesis
US10751360B1 (en) 2019-10-23 2020-08-25 Korea Institute Of Science And Technology Pharmaceutical composition for the prevention or treatment of nicotine addiction and withdrawal symptoms including miRNA
US10813935B2 (en) 2017-02-23 2020-10-27 Transgenex Nanobiotech, Inc. Methods and compositions for treating drug resistance in cancer
WO2020223121A1 (fr) 2019-04-30 2020-11-05 Dana-Farber Cancer Institute, Inc. Méthodes de traitement du cancer à l'aide de combinaisons d'agents anti-cx3cr1 et d'agents de blocage de points de contrôle immunitaires
WO2021072300A1 (fr) 2019-10-10 2021-04-15 Cellectar Biosciences, Inc. Conjugués phospholipide-flavagline et procédés d'utilisation de ceux-ci pour une thérapie anticancéreuse ciblée
EP3848383A2 (fr) 2014-08-04 2021-07-14 Oncotherapy Science, Inc. Peptide dérivé d'urlc10 et vaccin le contenant
WO2021173829A1 (fr) 2020-02-25 2021-09-02 Inovio Pharmaceuticals, Inc. Vaccins contre le coronavirus et leurs méthodes d'utilisation
US11135301B2 (en) 2016-09-14 2021-10-05 Duke University Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
US11155584B2 (en) 2016-09-23 2021-10-26 Duke University Unstructured non-repetitive polypeptides having LCST behavior
WO2021252354A1 (fr) 2020-06-12 2021-12-16 University Of Rochester Codage et expression d'arnt ace
US11246924B2 (en) 2016-04-01 2022-02-15 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
EP3964231A1 (fr) 2013-11-14 2022-03-09 Inovio Pharmaceuticals, Inc. Vaccin adn env plus rappel avec protéine contre le vih-1
EP3981416A2 (fr) 2014-08-04 2022-04-13 OncoTherapy Science, Inc. Peptide dérivé de koc1 et vaccin le comportant
US11306059B2 (en) 2017-10-25 2022-04-19 University Of South Florida Drug-induced activation of the Reelin signaling system
WO2022086852A2 (fr) 2020-10-19 2022-04-28 Dana-Farber Cancer Institute, Inc. Biomarqueurs germinaux de la réponse clinique et du bénéfice d'un traitement par inhibiteur de points de contrôle immunitaire
US11318155B2 (en) 2017-02-24 2022-05-03 University Of South Florida Hsp90 activator Aha1 drives production of pathological tau aggregates
WO2022104104A2 (fr) 2020-11-13 2022-05-19 Dana-Farber Cancer Institute, Inc. Vaccins à cellules de fusion personnalisés
WO2022159793A2 (fr) 2021-01-25 2022-07-28 Dana-Farber Cancer Institute, Inc. Procédés et compositions pour identifier un cancer de la prostate neuroendocrinien
WO2022178438A1 (fr) 2021-02-22 2022-08-25 Duke University Conjugués poegma-aptamères non immunogènes
US11439709B2 (en) 2014-11-17 2022-09-13 Cellectar Biosciences, Inc. Phospholipid ether analogs as cancer-targeting drug vehicles
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
EP4070818A2 (fr) 2014-01-06 2022-10-12 The Trustees of the University of Pennsylvania Anticorps pd1 et pdl1 et combinaisons de vaccin et leur utilisation pour l'immunothérapie
US11491206B1 (en) 2018-02-13 2022-11-08 Duke University Compositions and methods for the treatment of trail-resistant cancer
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
WO2022261183A2 (fr) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions et procédés de traitement et/ou d'identification d'un agent pour le traitement de cancers intestinaux
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2023004332A2 (fr) 2021-07-19 2023-01-26 New York University Compositions de vecteurs viraux adéno-associés et méthodes de promotion de la régénération musculaire
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
WO2023097119A2 (fr) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Méthodes et compositions pour moduler riok2
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
EP4219525A2 (fr) 2015-10-08 2023-08-02 OncoTherapy Science, Inc. Peptide dérivé de foxm1 et vaccin le contenant
WO2023150753A1 (fr) 2022-02-07 2023-08-10 University Of Rochester Séquences optimisées pour une expression d'adn améliorée et/ou une suppression de mutation non sens
WO2023158732A1 (fr) 2022-02-16 2023-08-24 Dana-Farber Cancer Institute, Inc. Procédés de diminution de l'alpha-synucléine pathologique à l'aide d'agents qui modulent fndc5 ou des fragments biologiquement actifs de celui-ci
US11744885B2 (en) 2020-05-14 2023-09-05 Inovio Pharmaceuticals, Inc. Vaccines for recurrent respiratory papillomatosis and methods of using the same
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
US11820822B2 (en) 2017-06-06 2023-11-21 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
EP4282883A2 (fr) 2014-08-04 2023-11-29 OncoTherapy Science, Inc. Peptide dérivé de cdca1 et vaccin le contenant
WO2024011033A1 (fr) 2022-07-07 2024-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogènes et procédés pour induire une réponse immunitaire
US11980671B2 (en) 2017-07-26 2024-05-14 Duke University Use of bacterial voltage gated ion channels for human therapies
WO2024102187A1 (fr) 2022-11-07 2024-05-16 Pinetree Therapeutics, Inc. Polythérapie comprenant des anticorps bispécifiques comprenant un domaine de liaison nrp1
WO2024129459A1 (fr) 2022-12-16 2024-06-20 University Of Rochester Réparation d'un dysfonctionnement de la barrière dans l'œsophage
US12018255B2 (en) 2017-12-08 2024-06-25 University Of Connecticut Compositions and methods for treating disorders of genomic imprinting
WO2024178172A1 (fr) 2023-02-23 2024-08-29 University Of Rochester Agents et méthodes de production de molécules de fil d'adn à extrémités fermées
US12098172B2 (en) 2017-07-31 2024-09-24 The Johns Hopkins University Compositions and methods for targeting MASAs to treat cancers with spliceosome mutations

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001349A (en) 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
EP1849477A1 (fr) * 1998-02-25 2007-10-31 THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY Utilisation d'activateurs de la pénétration cutanée et agents de dislocation de barrière visant à améliorer la réponse immune transcutanée
BR9908278A (pt) * 1998-02-25 2002-01-02 Iomai Corp Uso de agentes de melhoria de penetração e de rompimento de barreiras da pele, melhorar a resposta transcutânea imune induzida pela etoxina de ribosilatação de adp
EP1356821B1 (fr) * 1998-02-25 2007-06-20 THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY Utilisation d'amplificateurs de pénétration de la peau et d'agents de rupture de barrière afin d'augmenter la réponse immune transcutanée

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011092A1 (fr) * 1989-03-21 1990-10-04 Vical, Inc. Expression de sequences de polynucleotides exogenes chez un vertebre
US5580859A (en) * 1989-03-21 1996-12-03 Vical Incorporated Delivery of exogenous DNA sequences in a mammal

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3596660A (en) * 1969-05-12 1971-08-03 Illinois Tool Works Injection device

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011092A1 (fr) * 1989-03-21 1990-10-04 Vical, Inc. Expression de sequences de polynucleotides exogenes chez un vertebre
US5580859A (en) * 1989-03-21 1996-12-03 Vical Incorporated Delivery of exogenous DNA sequences in a mammal
US5589466A (en) * 1989-03-21 1996-12-31 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence

Non-Patent Citations (78)

* Cited by examiner, † Cited by third party
Title
"The Ultimate Delivery System: Lectro Patch Instructions," Advertisement by General Medical Company.
Acsadi, et al., "Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs," Nature, vol. 352, 29 Aug. 1991, pp. 815-818.
Acsadi, et al., Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs, Nature , vol. 352, 29 Aug. 1991, pp. 815 818. *
Barr, et al., "Systemic Delivery of Recombinant Proteins by Genetically Modified Myoblasts," Science, vol. 254, Dec. 1991, pp. 1507-1512.
Barr, et al., Systemic Delivery of Recombinant Proteins by Genetically Modified Myoblasts, Science , vol. 254, Dec. 1991, pp. 1507 1512. *
Been, et al., "One Binding Site Determines Sequence Specificity of Tetrahymena Pre-rRNA Self Splicing, Trans-Splicing, and RNA Enzyme Activity," Cell, vol. 47, 207-216, Oct. 24, 1986.
Been, et al., One Binding Site Determines Sequence Specificity of Tetrahymena Pre rRNA Self Splicing, Trans Splicing, and RNA Enzyme Activity, Cell , vol. 47, 207 216, Oct. 24, 1986. *
Caligiuri, et al., "Selective Modulation of Human Natural Killer Cells In Vivo After Prolonged Infusion of Low Dose Recombinant Interleukin 2," J. Clin. Invest., vol. 91, Jan. 1993, pp. 123-132.
Caligiuri, et al., Selective Modulation of Human Natural Killer Cells In Vivo After Prolonged Infusion of Low Dose Recombinant Interleukin 2, J. Clin. Invest. , vol. 91, Jan. 1993, pp. 123 132. *
Chang, et al., "Nasal Drug Delivery," Treatise on Controlled Drug Delivery, pp. 423-463.
Chang, et al., Nasal Drug Delivery, Treatise on Controlled Drug Delivery , pp. 423 463. *
Chien, "Mucosal Drug Delivery: Potential Routes for Noninvasive Systemic Administration," Novel Drug Delivery Systems, vol. 50, pp. 197-227.
Chien, "Nasal Drug Delivery and Delivery Systems," Novel Drug Delivery Systems, vol. 50, pp. 229-268.
Chien, "Transdermal Drug Delivery and Delivery Systems," Novel Drug Delivery Systems, vol. 50, pp. 301-380.
Chien, Mucosal Drug Delivery: Potential Routes for Noninvasive Systemic Administration, Novel Drug Delivery Systems , vol. 50, pp. 197 227. *
Chien, Nasal Drug Delivery and Delivery Systems, Novel Drug Delivery Systems , vol. 50, pp. 229 268. *
Chien, Transdermal Drug Delivery and Delivery Systems, Novel Drug Delivery Systems , vol. 50, pp. 301 380. *
Cohen, "Naked DNA Points Way to Vaccines," Science, vol. 259, 19 Mar. 1993, pp. 1691-1692.
Cohen, Naked DNA Points Way to Vaccines, Science , vol. 259, 19 Mar. 1993, pp. 1691 1692. *
Del Rey, et al., "Antidiabetic effects of interleukin 1," Proc. Natl. Acad. Sci. USA, vol. 86, pp. 5943-5947, Aug. 1989.
Del Rey, et al., Antidiabetic effects of interleukin 1, Proc. Natl. Acad. Sci. USA , vol. 86, pp. 5943 5947, Aug. 1989. *
Donohue, et al., "In Vivo Administration of Purified Jurkat-derived Interleukin 2 in Mice," Cancer Research, vol. 44, Apr. 1984, pp. 1380-1386.
Donohue, et al., In Vivo Administration of Purified Jurkat derived Interleukin 2 in Mice, Cancer Research , vol. 44, Apr. 1984, pp. 1380 1386. *
Ferrara, et al., "Highly Potent Transcriptional Activation by 16-ene Derivatives of 1,25-Dihydroxyvitamin D3 ,", Journal of Biological Chemistry, vol. 269, No. 4, Jan. 18, 1994, pp. 2971-2981.
Ferrara, et al., Highly Potent Transcriptional Activation by 16 ene Derivatives of 1,25 Dihydroxyvitamin D 3 , , Journal of Biological Chemistry , vol. 269, No. 4, Jan. 18, 1994, pp. 2971 2981. *
Gillies, et al., "Expression of Human Anti-Tetanus Toxoid Antibody in Transfected Murine Myeloma Cells," Bio/Technology, vol. 7, Aug. 1989, pp. 799-804.
Gillies, et al., Expression of Human Anti Tetanus Toxoid Antibody in Transfected Murine Myeloma Cells, Bio/Technology , vol. 7, Aug. 1989, pp. 799 804. *
Goldstein, et al., "Repetitive Weekly Cycles of Interleukin 2: Effect of Outpatient Treatment with a Lower Dose of Interleukin 2 . . . ," Cancer Research, vol. 49, pp. 6832-6839, Dec. 1, 1989.
Goldstein, et al., Repetitive Weekly Cycles of Interleukin 2: Effect of Outpatient Treatment with a Lower Dose of Interleukin 2 . . . , Cancer Research , vol. 49, pp. 6832 6839, Dec. 1, 1989. *
Gorman, et al., "The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells . . . ," Proc. Natl. Acad. Sci. USA, vol. 79, pp. 6777-6781, Nov. 1982.
Gorman, et al., The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells . . . , Proc. Natl. Acad. Sci. USA , vol. 79, pp. 6777 6781, Nov. 1982. *
Hefeneider, et al., "In Vivo Interleukin 2 Administration Augments the Generation of Alloreactive Cytolytic T Lymphocytes and Resident Natural Killer Cells," Journal of Immunology, vol. 130, No. 1, Jan. 1983, 222-227.
Hefeneider, et al., In Vivo Interleukin 2 Administration Augments the Generation of Alloreactive Cytolytic T Lymphocytes and Resident Natural Killer Cells, Journal of Immunology , vol. 130, No. 1, Jan. 1983, 222 227. *
Huang, et al., "Role of Bone Marrow-Derived Cells in Presenting MHC Class 1-Restricted Tumor Antigens," Science, vol. 264, 13 May 1994, pp. 961-965.
Huang, et al., Role of Bone Marrow Derived Cells in Presenting MHC Class 1 Restricted Tumor Antigens, Science , vol. 264, 13 May 1994, pp. 961 965. *
Israeli, et al., "Expression of the Prostate-specific Membrane Antigen," Cancer Res., 54:1807-1811 (1994).
Israeli, et al., Expression of the Prostate specific Membrane Antigen, Cancer Res. , 54:1807 1811 (1994). *
Kaplan, et al., "Rational Immunotherapy with Interleukin 2," Bio/Technology, vol. 10, Feb. 1992, pp. 157-162.
Kaplan, et al., Rational Immunotherapy with Interleukin 2, Bio/Technology , vol. 10, Feb. 1992, pp. 157 162. *
Krieg, et al., "Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs," Nucleic Acids Research, IRL Press Limited, vol. 12, No. 18, 1984, pp. 7057-7070.
Krieg, et al., Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs, Nucleic Acids Research, IRL Press Limited, vol. 12, No. 18, 1984, pp. 7057 7070. *
Liang, et al., "Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction," Science, vol. 257, 14 Aug. 1992, pp. 967-971.
Liang, et al., Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction, Science , vol. 257, 14 Aug. 1992, pp. 967 971. *
Lisitsyn, et al., "Cloning the Differences Between Two Complex Genomes," Science, vol. 259, 12 Feb. 1993, pp. 946-951.
Lisitsyn, et al., Cloning the Differences Between Two Complex Genomes, Science , vol. 259, 12 Feb. 1993, pp. 946 951. *
Lotz, et al., Brief Definitive Report, J. Exp. Med. , vol. 167, Mar. 1988, 1253 1258. *
Lotz, et al., Brief Definitive Report, J. Exp. Med., vol. 167, Mar. 1988, 1253-1258.
Mader, et al., "A steroid-inducible promoter for the controlled overexpression f cloned genes in eukaryotic cells," Proc. Natl. Acad. Sci. USA, vol. 90, pp. 5603-5607, Jun. 1993.
Mader, et al., A steroid inducible promoter for the controlled overexpression f cloned genes in eukaryotic cells, Proc. Natl. Acad. Sci. USA , vol. 90, pp. 5603 5607, Jun. 1993. *
Mamula, et al., "B Cells Process and Present Lupus Autoantigens that Initiate Autoimmune T Cell Responses," Journal of Immunology, 1994, 152:1453-1461.
Mamula, et al., B Cells Process and Present Lupus Autoantigens that Initiate Autoimmune T Cell Responses, Journal of Immunology , 1994, 152:1453 1461. *
Norton, et al., "Bacterial B-Galactosidase as a Marker of Rous Sarcoma Virus Gene Expression and Replication," Molecular and Cellular Biology, vol. 5, No. 2, Feb. 1985, pp. 281-290.
Norton, et al., Bacterial B Galactosidase as a Marker of Rous Sarcoma Virus Gene Expression and Replication, Molecular and Cellular Biology , vol. 5, No. 2, Feb. 1985, pp. 281 290. *
Robinson, et al., "Use of Direct DNA Inoculations to Elicit Protective Immune Responses," Journal of Cellular Biochemistry, Supp. 17D, 1993, p. 92.
Robinson, et al., Use of Direct DNA Inoculations to Elicit Protective Immune Responses, Journal of Cellular Biochemistry , Supp. 17D, 1993, p. 92. *
Shastri, et al., "Endogenous Generation and Presentation of the Ovalbumin Peptide/Kb Complex to T Cells," Journal of Immunology, vol. 150, No. 7, pp. 2724-2736, Apr. 1, 1993.
Shastri, et al., Endogenous Generation and Presentation of the Ovalbumin Peptide/K b Complex to T Cells, Journal of Immunology , vol. 150, No. 7, pp. 2724 2736, Apr. 1, 1993. *
Shields, et al., "Calorie restriction suppresses subgenomic mink cytopathic focus-forming murine leukemia virus transcription and frequency . . . ," Proc. Natl. Acad. Sci. USA, vol. 88, pp. 11138-11142, Dec. 1991.
Shields, et al., Calorie restriction suppresses subgenomic mink cytopathic focus forming murine leukemia virus transcription and frequency . . . , Proc. Natl. Acad. Sci. USA , vol. 88, pp. 11138 11142, Dec. 1991. *
Sloan, "Use of Solubility Parameters from Regular Solution Theory to Describe Partitioning-Driven Processes," Prodrugs: Topical and Ocular Drug Delivery, vol. 53, pp. 179-204.
Sloan, Use of Solubility Parameters from Regular Solution Theory to Describe Partitioning Driven Processes, Prodrugs: Topical and Ocular Drug Delivery , vol. 53, pp. 179 204. *
Stribling, et al., "Aerosol gene delivery in vivo," Proc. Natl. Acad. Sci. USA, vol. 89, pp. 11277-11281 Dec. 1992.
Stribling, et al., Aerosol gene delivery in vivo, Proc. Natl. Acad. Sci. USA , vol. 89, pp. 11277 11281 Dec. 1992. *
Tang, et al., "Genetic immunization is a simple method for eliciting an immune response," Nature, vol. 356, 12 Mar. 1992, pp. 152-154.
Tang, et al., Genetic immunization is a simple method for eliciting an immune response, Nature , vol. 356, 12 Mar. 1992, pp. 152 154. *
Teppler, et al., "Prolonged Immunostimulatory Effect of Low-Dose Polyethylene Glycol Interleukin 2 in Patients with Human Immunodeficiency Virus Type 1 Infection," J. Exp. Med., vol. 177, Feb. 1993, 483-492.
Teppler, et al., Prolonged Immunostimulatory Effect of Low Dose Polyethylene Glycol Interleukin 2 in Patients with Human Immunodeficiency Virus Type 1 Infection, J. Exp. Med. , vol. 177, Feb. 1993, 483 492. *
The Ultimate Delivery System: Lectro Patch Instructions, Advertisement by General Medical Company. *
Tice, et al., "Parenteral Drug Delivery: Injectables," Treatise on Controlled Drug Delivery, pp. 315-339.
Tice, et al., Parenteral Drug Delivery: Injectables, Treatise on Controlled Drug Delivery , pp. 315 339. *
Ulmer, et al., "Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein," Science, vol. 259, 19 Mar. 1993, pp. 1745-1748.
Ulmer, et al., Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein, Science , vol. 259, 19 Mar. 1993, pp. 1745 1748. *
Ward et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli", Nature, vol. 341, 12 Oct. 1989, pp. 544-546.
Ward et al., Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli , Nature , vol. 341, 12 Oct. 1989, pp. 544 546. *
Wolff, et al., "Conditions Affecting Direct Gene Transfer into Rodent Muscle In Vivo", BioTechniques vol. 11, No. 4 (1991), pp. 474-485.
Wolff, et al., "Indirect Gene Transfer into Mouse Muscle in Vivo," Science, vol. 24, Mar. 1990, pp. 1465-1468.
Wolff, et al., Conditions Affecting Direct Gene Transfer into Rodent Muscle In Vivo , BioTechniques vol. 11, No. 4 (1991), pp. 474 485. *
Wolff, et al., Indirect Gene Transfer into Mouse Muscle in Vivo, Science , vol. 24, Mar. 1990, pp. 1465 1468. *

Cited By (447)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951845B2 (en) * 1993-08-26 2005-10-04 The Regents Of The University Of California Method for treating allergic lung disease
US6348449B1 (en) * 1993-09-21 2002-02-19 The Trustees Of The University Of Pennsylvania Methods of inducing mucosal immunity
US7825097B2 (en) 1993-10-22 2010-11-02 Institut Pasteur Nucleotide vector vaccine for immunization against hepatitis
US6635624B1 (en) 1993-10-22 2003-10-21 Institut Pasteur Nucleotide vector composition containing such vector and vaccine for immunization against hepatitis
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US7723022B2 (en) 1994-07-15 2010-05-25 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US8158592B2 (en) 1994-07-15 2012-04-17 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acid molecules
US20060089326A1 (en) * 1994-07-15 2006-04-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7223741B2 (en) 1994-07-15 2007-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US8129351B2 (en) 1994-07-15 2012-03-06 The University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6653292B1 (en) 1994-07-15 2003-11-25 University Of Iowa Research Foundation Method of treating cancer using immunostimulatory oligonucleotides
US7517861B2 (en) 1994-07-15 2009-04-14 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US8058249B2 (en) 1994-07-15 2011-11-15 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20040087534A1 (en) * 1994-07-15 2004-05-06 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US8114848B2 (en) 1994-07-15 2012-02-14 The United States Of America As Represented By The Department Of Health And Human Services Immunomodulatory oligonucleotides
US7888327B2 (en) 1994-07-15 2011-02-15 University Of Iowa Research Foundation Methods of using immunostimulatory nucleic acid molecules to treat allergic conditions
US7524828B2 (en) 1994-07-15 2009-04-28 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US8008266B2 (en) 1994-07-15 2011-08-30 University Of Iowa Foundation Methods of treating cancer using immunostimulatory oligonucleotides
US7402572B2 (en) 1994-07-15 2008-07-22 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US8309527B2 (en) 1994-07-15 2012-11-13 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US7879810B2 (en) 1994-07-15 2011-02-01 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US8258106B2 (en) 1994-07-15 2012-09-04 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6359054B1 (en) 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US7780991B2 (en) 1994-12-02 2010-08-24 Quadrant Drug Delivery Limited Solid dose delivery vehicle and methods of making same
US7785631B2 (en) 1994-12-02 2010-08-31 Quadrant Drug Delivery Limited Solid dose delivery vehicle and methods of making same
US7744925B2 (en) 1994-12-02 2010-06-29 Quadrant Drug Delivery Limited Solid dose delivery vehicle and methods of making same
US20080139494A1 (en) * 1994-12-16 2008-06-12 Weiner David B Methods of inducing mucosal immunity
US7220728B2 (en) 1994-12-16 2007-05-22 The Trustees Of The University Of Pennsylvania Methods of inducing mucosal immunity
US8536145B2 (en) 1994-12-16 2013-09-17 The Trustees Of The University Of Pennsylvania Methods of inducing mucosal immunity
US20090149406A1 (en) * 1995-09-15 2009-06-11 Centelion Plasmid PXL3179 or NV1FGF
US20090130674A1 (en) * 1995-09-15 2009-05-21 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US7807444B2 (en) * 1995-09-15 2010-10-05 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US20070015282A1 (en) * 1995-09-15 2007-01-18 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US20070141708A2 (en) * 1995-09-15 2007-06-21 Centelion Circular dna molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US6942862B2 (en) * 1996-04-01 2005-09-13 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
US20060008479A1 (en) * 1996-04-01 2006-01-12 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
US20090252713A1 (en) * 1996-09-13 2009-10-08 Fabienne Soubrier Circular dna molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US20100203074A1 (en) * 1996-09-17 2010-08-12 Matti Sallberg Compositions and methods for treating intracellular diseases
US7763589B2 (en) 1996-09-17 2010-07-27 Novartis Vaccines And Diagnostics, Inc. Compositions and methods for treating intracellular diseases
US8911742B2 (en) 1996-11-14 2014-12-16 The United States Of America As Represented By The Secretary Of The Army Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US7001890B1 (en) 1997-01-23 2006-02-21 Coley Pharmaceutical Gmbh Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination
US20050054601A1 (en) * 1997-01-23 2005-03-10 Coley Pharmaceutical Gmbh Pharmaceutical composition comprising a polynucleotide and optionally an antigen especially for vaccination
US20020155093A1 (en) * 1997-02-18 2002-10-24 Houghton Alan N. Method for stimulation of an immune response to a differentiation antigen stimulated by an altered antigen
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
US7488490B2 (en) 1997-03-10 2009-02-10 University Of Iowa Research Foundation Method of inducing an antigen-specific immune response by administering a synergistic combination of adjuvants comprising unmethylated CpG-containing nucleic acids and a non-nucleic acid adjuvant
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US6821957B2 (en) 1997-05-20 2004-11-23 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US6528315B2 (en) 1997-06-30 2003-03-04 Aventis Pharma S.A. Method for transferring nucleic acid into multicelled eukaryotic organism cells and combination therefor
US6939862B2 (en) 1997-06-30 2005-09-06 Aventis Pharma S.A. Method for transferring nucleic acid into striated muscles
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US20090035252A1 (en) * 1997-07-10 2009-02-05 Kundig Thomas M Method of inducing a CTL response
US20020007173A1 (en) * 1997-07-10 2002-01-17 Kundig Thomas M. Method of inducing a CTL response
US7364729B2 (en) 1997-07-10 2008-04-29 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US20060153858A1 (en) * 1997-07-10 2006-07-13 Kundig Thomas M Method of inducing a CTL response
US8372393B2 (en) 1997-07-10 2013-02-12 Mannkind Corporation Method of inducing a CTL response
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
WO1999008713A1 (fr) * 1997-08-13 1999-02-25 The Uab Research Foundation Vaccination par application topique de vecteurs genetiques
US6582704B2 (en) 1997-10-09 2003-06-24 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US20040229809A1 (en) * 1997-10-09 2004-11-18 Zycos Inc., A Delaware Corporation Immunogenic peptides from the HPV E7 protein
US7097843B2 (en) 1997-10-09 2006-08-29 Mgi Pharma Biologics, Inc. Immunogenic peptides from the HPV E7 protein
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
EP2218732A1 (fr) 1997-11-28 2010-08-18 Merck Serono Biodevelopment Séquence génomique de Chlamydia pneumoniae, polypeptides, fragments et leurs utilisations, en particulier pour le diagnostic, la prévention et le traitement de l'infection
EP2218731A1 (fr) 1997-11-28 2010-08-18 Merck Serono Biodevelopment Séquence génomique de Chlamydia pneumoniae, polypeptides, fragments et leurs utilisations, en particulier pour le diagnostic, la prévention et le traitement de l'infection
EP2228384A1 (fr) 1997-11-28 2010-09-15 Merck Serono Biodevelopment Séquence génomique de Chlamydia pneumoniae, polypeptides, fragments et leurs utilisations, en particulier pour le diagnostic, la prévention et le traitement de l'infection
EP2218730A1 (fr) 1997-11-28 2010-08-18 Merck Serono Biodevelopment Séquence génomique de Chlamydia pneumoniae, polypeptides, fragments et leurs utilisations, en particulier pour le diagnostic, la prévention et le traitement de l'infection
EP2228385A1 (fr) 1997-11-28 2010-09-15 Merck Serono Biodevelopment Séquence génomique de Chlamydia pneumoniae, polypeptides, fragments et leurs utilisations, en particulier pour le diagnostic, la prévention et le traitement de l'infection
US6432641B1 (en) 1997-12-16 2002-08-13 University Of Saskatchewan Technologies Inc. Conductive metal-containing nucleic acids
US6087341A (en) * 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
WO1999041366A1 (fr) * 1998-02-12 1999-08-19 The Board Of Trustees Of The Leland Stanford Junior University Introduction d'acide nucleique dans des cellules cutanees, par application topique
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
WO1999046988A1 (fr) * 1998-03-20 1999-09-23 Genzyme Corporation Compositions et methodes de vaccination specifique de l'antigene
AU759765B2 (en) * 1998-03-20 2003-05-01 Genzyme Corporation Compositions and methods for antigen-specific vaccination
WO1999051748A2 (fr) 1998-04-07 1999-10-14 Corixa Corporation Proteines hybrides d'antigenes de mycobacterium tuberculosis et leurs utilisations
WO1999058658A2 (fr) 1998-05-13 1999-11-18 Epimmune, Inc. Vecteurs d'expression destines a stimuler une reponse immunitaire et procedes de leur utilisation
US8574599B1 (en) 1998-05-22 2013-11-05 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US7741300B2 (en) 1998-06-25 2010-06-22 National Jewish Medical And Research Center Methods of using nucleic acid vector-lipid complexes
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US7851591B1 (en) 1998-10-29 2010-12-14 Dana Farber Cancer Institute, Inc. Cancer immunotherapy and diagnosis using universal tumor associated antigens, including hTERT
WO2000025813A1 (fr) * 1998-10-29 2000-05-11 Dana-Farber Cancer Institute IMMUNOTHERAPIE ET DIAGNOSTIC DU CANCER AU MOYEN D'ANTIGENES UNIVERSELS ASSOCIES A DES TUMEURS TELS QUE hTERT
US20070237781A1 (en) * 1998-12-16 2007-10-11 University Of Saskatchewan Technologies, Inc. Biologically active metal-containing nucleic acids
US7160869B2 (en) 1998-12-16 2007-01-09 University Of Saskatchewan Biologically active metal-containing nucleic acids
EP2368575A2 (fr) 1999-04-08 2011-09-28 Intercell USA, Inc. Formulation seche pour immunisation transcutanee
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
US9248177B2 (en) 1999-05-03 2016-02-02 Uab Research Foundation Vaccine and drug delivery by intranasal application of vector and vector extracts
WO2000066179A1 (fr) * 1999-05-03 2000-11-09 The Uab Research Foundation Immunisation genetique non invasive, produits d'expression obtenus a partir de celle-ci et utilisations
US6716623B2 (en) 1999-05-06 2004-04-06 Wake Forest University School Of Medicine Compositions and methods for identifying antigens which elicit an immune response
US20040096426A1 (en) * 1999-05-06 2004-05-20 Wake Forest University Compositions and methods for identifying antigens which elicit an immune response
US6500641B1 (en) 1999-05-06 2002-12-31 Wake Forest University School Of Medicine Compositions and methods for identifying antigens which elicit an immune response
US7749752B2 (en) 1999-05-06 2010-07-06 Wake Forest University Health Sciences Compositions and methods for identifying antigens which elicit an immune response
WO2000067761A1 (fr) * 1999-05-06 2000-11-16 Wake Forest University Compositions et procedes d'identification d'antigenes provoquant une reponse immunitaire
US20080131871A1 (en) * 1999-05-06 2008-06-05 Wake Forest University Health Sciences Compositions and methods for identifying antigens which elicit an immune response
US7273752B2 (en) 1999-05-06 2007-09-25 Wake Forest University Health Sciences Compositions and methods for identifying antigens which elicit an immune response
US20020151515A1 (en) * 1999-06-18 2002-10-17 Roberts Bruce L. Preparation and use of superior vaccines
US20080112946A1 (en) * 1999-06-28 2008-05-15 Gerald Koelsch Catalytically active recombinant memapsin and methods of use thereof
US20080021196A1 (en) * 1999-06-28 2008-01-24 The Board Of Trustees Of The University Of Illinois Inhibitors of memapsin 2 and use thereof
US7678760B2 (en) 1999-06-28 2010-03-16 The Board Of Trustees Of The University Of Illinois Inhibitors of Memapsin 2 and use thereof
US7829669B2 (en) 1999-06-28 2010-11-09 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
US20030119773A1 (en) * 1999-07-02 2003-06-26 Raz Eyal R. Method for enhancing an immune response
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US6835184B1 (en) 1999-09-24 2004-12-28 Becton, Dickinson And Company Method and device for abrading skin
US20060116342A1 (en) * 1999-10-07 2006-06-01 Cornell Research Foundation, Inc. Protective immunity or immunological tolerance induced with RNA, particularly total cellular RNA
US20070190073A1 (en) * 1999-11-15 2007-08-16 Stephen Tuck Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US7628990B2 (en) 1999-11-15 2009-12-08 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
EP2177534A2 (fr) 1999-11-18 2010-04-21 Pharmexa Inc. Analogues hétéroclites de classe 1 épitopes
EP1842549A2 (fr) 1999-12-28 2007-10-10 Pharmexa Inc. Minigènes optimisés et peptides encodées associées
US20040067902A9 (en) * 2000-02-03 2004-04-08 Bratzler Robert L. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20030087848A1 (en) * 2000-02-03 2003-05-08 Bratzler Robert L. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US7491537B2 (en) 2000-03-03 2009-02-17 Genetronics Biomedical Corporation Nucleic acid formulations for gene delivery and methods of use
US7173116B2 (en) * 2000-03-03 2007-02-06 Genetronics Biomedical Corporation Nucleic acid formulations for gene delivery and methods of use
US20070213287A1 (en) * 2000-03-03 2007-09-13 Genetronics, Inc. Nucleic Acid Formulations for Gene Delivery and Methods of Use
US20030109478A1 (en) * 2000-03-03 2003-06-12 Valentis, Inc. Nucleic acid formulations for gene delivery and methods of use
US7094408B2 (en) 2000-04-28 2006-08-22 The United States Of America As Represented By The Department Of Health And Human Services Immunogenicity using a combination of DNA and vaccinia virus vector vaccines
US20040033237A1 (en) * 2000-04-28 2004-02-19 Genoveffa Franchini Immunogenicity using a combination of dna and vaccinia virus vector vaccines
US20050069982A1 (en) * 2000-04-28 2005-03-31 Simard John J.L. Method of epitope discovery
US20050130920A1 (en) * 2000-04-28 2005-06-16 Simard John J. Epitope synchronization in antigen presenting cells
US20070184062A1 (en) * 2000-04-28 2007-08-09 Simard John J Epitope synchronization in antigen presenting cells
US7771729B2 (en) 2000-04-28 2010-08-10 The United States Of America As Represented By The Department Of Health And Human Services Methods of potentiating HIV-1-specific CD8+ immune responses involving the concomitant administration of DNA and ALVAC expression vectors
US20060240042A1 (en) * 2000-04-28 2006-10-26 Govt. Of The U.S.A As Represented By The Secretary Of The Department Of Health And Human Services Immunogenicity using a combination of dna and vaccinia virus vector vaccines
US20070269464A1 (en) * 2000-04-28 2007-11-22 Simard John J Epitope synchronization in antigen presenting cells
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US20100291037A1 (en) * 2000-04-28 2010-11-18 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Immunogenicity using a combination of dna and vaccinia virus vector vaccines
US20040033234A1 (en) * 2000-05-10 2004-02-19 Neil Berinstein Immunogenic polypetides encoded by mage minigenes and uses thereof
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
US7731968B2 (en) 2000-05-22 2010-06-08 Becton, Dickinson And Company Topical delivery of vaccines
US20080009785A1 (en) * 2000-05-22 2008-01-10 Mikszta John A Topical delivery of vaccines
US6595947B1 (en) 2000-05-22 2003-07-22 Becton, Dickinson And Company Topical delivery of vaccines
WO2001089622A1 (fr) 2000-05-22 2001-11-29 Becton, Dickinson And Company Applicateur dote d'une surface abrasive recouverte d'une substance devant etre appliquee sur la peau
US6686188B2 (en) 2000-05-26 2004-02-03 Amersham Plc Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
US6656700B2 (en) 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
US7534772B2 (en) 2000-06-22 2009-05-19 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
EP2075582A2 (fr) 2000-07-12 2009-07-01 Agensys, Inc. Nouvel antigène de tumeur utile dans le diagnostic et la thérapie des cancers de la vessie, ovaire, poumon et rein
EP2022797A2 (fr) 2000-08-28 2009-02-11 Agensys, Inc. Acide nucléique et protéine correspondante intitulée 85P1B3 utile dans le traitement et la détection du cancer
EP1911461A2 (fr) 2000-10-19 2008-04-16 Pharmexa Inc. Peptides de liaisons HLA de classe I et II et leurs utilisations
US20030028000A1 (en) * 2000-10-31 2003-02-06 Nazneen Aziz CYP1B1 nucleic acids and methods of use
US20100233087A1 (en) * 2000-10-31 2010-09-16 Mgi Pharma Biologics, Inc. Cyp1b1 nucleic acids and methods of use
US7241742B2 (en) * 2000-10-31 2007-07-10 Mgi Pharma Biologics, Inc. CYP1B1 nucleic acids and methods of use
US8158594B2 (en) 2000-10-31 2012-04-17 Eisai Inc. CYP1B1 nucleic acids and methods of use
US6709844B1 (en) 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US20030180949A1 (en) * 2000-11-16 2003-09-25 John Levy Avoidance of undesirable replication intermediates in plasmid propagation
US7390654B2 (en) 2000-11-16 2008-06-24 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US8143010B2 (en) 2000-12-04 2012-03-27 Institute For Systems Biology Prostate-specific polypeptide PAMP and encoding nucleic acid molecules
US20090042202A1 (en) * 2000-12-04 2009-02-12 Institute For Systems Biology Prostate-specific polypeptide pamp and encoding nucleic acid molecules
EP2311863A1 (fr) 2001-03-05 2011-04-20 Agensys, Inc. Acide nucléique et protéine correspondante 121P1F1 utilisés dans le traitement et la détection du cancer
EP2366711A2 (fr) 2001-03-14 2011-09-21 Agensys, Inc. Acide nucléique et protéine correspondante 125P5C8 utilisés dans le traitement et la détection du cancer
US20020142337A1 (en) * 2001-03-29 2002-10-03 Edwards David N. Hybrid gene libraries and uses thereof
US20030072764A1 (en) * 2001-04-05 2003-04-17 O'hagan Derek Mucosal boosting following parenteral priming
EP2280030A2 (fr) 2001-04-10 2011-02-02 Agensys, Inc. Acides nucléiques et protéines correspondantes utiles dans la détection et le traitement des différents cancers
US20020175317A1 (en) * 2001-05-24 2002-11-28 Lee Jeremy Stuart Nucleic acid circuit elements and methods
WO2002100476A2 (fr) 2001-06-08 2002-12-19 Becton, Dickinson And Company Dispositif permettant de manipuler une aiguille ou un ensemble d'abrasion
US7186235B2 (en) 2001-06-08 2007-03-06 Becton, Dickinson And Company Device for manipulating a needle or abrader array and method of use
US20020188245A1 (en) * 2001-06-08 2002-12-12 Martin Frank E. Device for manipulating a needle or abrader array and method of use
US20030176398A1 (en) * 2001-06-11 2003-09-18 Gallop Mark A. Prodrugs of GABA analogs, compositions and uses thereof
WO2003015615A2 (fr) 2001-08-15 2003-02-27 Brown University Research Foundation Traitement de dystrophies musculaires et de troubles connexes
EP2287186A1 (fr) 2001-09-06 2011-02-23 Agensys, Inc. Acide nucléique et protéine corréspondante designés par STEAP-1 utiles dans le traitement et la détection du cancer
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
US20030093040A1 (en) * 2001-10-29 2003-05-15 Mikszta John A. Method and device for the delivery of a substance
EP2302041A1 (fr) 2001-11-07 2011-03-30 Agensys, Inc. Acide nucléique et protéine correspondante intitulée 161P2F10B utile pour le traitement et la détection du cancer
US8637305B2 (en) 2001-11-07 2014-01-28 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
US7232682B2 (en) 2001-11-07 2007-06-19 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
US8252916B2 (en) 2001-11-07 2012-08-28 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
US20040132088A1 (en) * 2001-11-07 2004-07-08 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens and methods for their design
US20040203051A1 (en) * 2001-11-07 2004-10-14 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens and methods for their design
US20030228634A1 (en) * 2001-11-07 2003-12-11 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens and methods for their design
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
AU2003224601B2 (en) * 2002-01-18 2008-12-04 The Uab Research Foundation Vaccination and vaccine and drug delivery by topical application of vectors and vector extracts recombinant vectors, and noninvasive genetic immunization, expression products therefrom and uses thereof
WO2003070920A1 (fr) * 2002-01-18 2003-08-28 The Uab Research Foundation Vaccination, administration de vaccins et de medicaments par application topique de vecteurs et de vecteurs recombinants d'extraits de vecteurs, immunisation genetique non invasive, produits d'expression issus de ces elements et leurs utilisations
US20030224392A1 (en) * 2002-01-28 2003-12-04 Manuel Engelhorn Method for identification of mutant antigens with enhanced immunogenicity
US20060094006A1 (en) * 2002-05-01 2006-05-04 Genoveffa Franchini Immunotherapy regimens in hiv-infected patients
US20060110790A1 (en) * 2002-05-06 2006-05-25 Robert Molday Expression system for large functional proteins
US20030224485A1 (en) * 2002-05-06 2003-12-04 Molday Robert S. Expression system for ABC transporters
EP2070949A2 (fr) 2002-06-10 2009-06-17 Vaccinex, Inc. Gène s'exprimant par action différentielle dans le cancer du sein et de la vessie, et polypeptides codés
EP2301954A2 (fr) 2002-08-16 2011-03-30 Agensys, Inc. Acides nucléiques et protéines correspondantes 282G1G3 utilisées dans le traitement et la détection du cancer
EP2332966A1 (fr) 2002-08-16 2011-06-15 Agensys, Inc. Acides nucléiques et protéines correspondantes 191P4D12(b) utilisées dans le traitement et la détection du cancer
US20070224210A1 (en) * 2002-08-19 2007-09-27 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids
US8304396B2 (en) 2002-08-19 2012-11-06 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids
US8283328B2 (en) 2002-08-19 2012-10-09 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids
US8075826B2 (en) 2002-08-29 2011-12-13 Becton, Dickinson And Company Microprotrusion arrays and methods for using same to deliver substances into tissue
US7422567B2 (en) 2002-08-29 2008-09-09 Becton, Dickinson And Company Microabrader with controlled abrasion features
WO2004020015A2 (fr) 2002-08-29 2004-03-11 Becton Dickinson And Company Matrices de microprotuberances et procede permettant d'utiliser ces matrices pour l'administration de substances a un tissu
WO2004019777A2 (fr) 2002-08-29 2004-03-11 Becton Dickinson And Company Administration d'une substance par l'intermediaire d'une surface micro-abrasive rotative
US20040064087A1 (en) * 2002-08-29 2004-04-01 Lastovich Alexander G. Microabrader with controlled abrasion features
US20090270792A1 (en) * 2002-08-29 2009-10-29 Lastovich Alexander G Microprotrusion arrays and methods for using same to deliver substances into tissue
US7316671B2 (en) 2002-08-29 2008-01-08 Becton, Dickinson And Company Microprotrusion arrays and methods for using same to deliver substances into tissue
US20040143211A1 (en) * 2002-08-29 2004-07-22 Haider M. Ishaq Substance delivery via a rotating microabrading surface
US7166086B2 (en) 2002-08-29 2007-01-23 Becton, Dickinson And Company Substance delivery via a rotating microabrading surface
US20040077994A1 (en) * 2002-08-29 2004-04-22 Lastovich Alexander G. Microprotrusion arrays and methods for using same to deliver substances into tissue
EP3075410A1 (fr) 2002-08-29 2016-10-05 Becton Dickinson and Company Matrices de microprotuberances et procede permettant d'utiliser ces matrices pour l'administration de substances a un tissu
US20060247190A1 (en) * 2002-10-21 2006-11-02 Kathleen Beach Compositions and methods for treating human papillomavirus mediated disease
US20040223949A1 (en) * 2002-10-22 2004-11-11 Sunnybrook And Women's College Health Sciences Center Aventis Pasteur, Ltd. Vaccines using high-dose cytokines
WO2004050828A2 (fr) 2002-11-27 2004-06-17 Agensys, Inc. Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer
EP1903056A2 (fr) 2002-12-10 2008-03-26 Idm Pharma, Inc. Peptides d'antigènes HLA-A1, -A2 -A3, -A24, -B7 et -B44 associés aux tumeurs et compositions
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
EP2343315A2 (fr) 2003-02-10 2011-07-13 Agensys, Inc. Acide nucléique et protéine correspondante appelée 158P1D7 utile pour le traitement et la détection de cancer de la vessie et autres
US20040235019A1 (en) * 2003-03-06 2004-11-25 Agouron Pharmaceuticals, Inc. Diagnostics and therapeutics for the gene expression signature of PPAR-gamma receptor ligand
US20070037151A1 (en) * 2003-04-28 2007-02-15 Babe Lilia M Cd4+ human papillomavirus (hpv) epitopes
EP2319524A1 (fr) 2003-05-30 2011-05-11 Agensys, Inc. Variantes de l'antigène de cellules souches de la prostate (PSCA) et sous-séquences de celles-ci
US20040244742A1 (en) * 2003-06-05 2004-12-09 Caterpillar Inc. Control system and method for engine valve actuator
US20050118186A1 (en) * 2003-06-17 2005-06-02 Chih-Sheng Chiang Combinations of tumor-associated antigens in compositions for various types of cancers
US20090148478A1 (en) * 2003-06-17 2009-06-11 Mannkind Corporation Combinations of tumor-associated antigens in compositions for various types of cancers
US20080131453A1 (en) * 2003-08-12 2008-06-05 Medical College Of Georgia Research Institute Campylobacter Jejuni Outer Membrane Protein Immunogenic Composition
US8961477B2 (en) 2003-08-25 2015-02-24 3M Innovative Properties Company Delivery of immune response modifier compounds
US20070128630A1 (en) * 2003-09-05 2007-06-07 Fiona Harding HPV CD8+ T-cell epitopes
US7153659B2 (en) 2003-09-05 2006-12-26 Genencor International, Inc. HPV CD8+ T-cell epitopes
US20050181458A1 (en) * 2003-09-05 2005-08-18 Fiona Harding HPV CD8+ T-cell epitopes
US7329498B2 (en) 2003-09-05 2008-02-12 Genencor International, Inc. HPV CD8+ T-cell epitopes
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
US7556821B2 (en) 2004-05-13 2009-07-07 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
WO2005112984A3 (fr) * 2004-05-13 2006-04-20 Alza Corp Appareil et procédé pour la délivrance transdermique d'agents à base d'hormone parathyroïde
US8361022B2 (en) 2004-05-13 2013-01-29 Alza Corporation Apparatus for transdermal delivery of parathyroid hormone agents
US20050256045A1 (en) * 2004-05-13 2005-11-17 Mahmoud Ameri Apparatus and method for transdermal delivery of parathyroid hormone agents
EP2428522A1 (fr) 2004-05-28 2012-03-14 Agensys, Inc. Anticorps se liant à des protéines PSCA pour le diagnostic du cancer
EP2583981A2 (fr) 2004-05-28 2013-04-24 Agensys, Inc. Anticorps et molécules correspondantes se liant aux protéines PSCA
WO2005118864A2 (fr) 2004-05-28 2005-12-15 Agensys, Inc. Anticorps et molecules apparentees qui se lient aux proteines d'antigene des cellules souches de prostate (proteines de psca)
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
WO2006031391A2 (fr) 2004-08-25 2006-03-23 Becton, Dickinson And Company Procede et dispositif pour l'administration d'une substance comportant un couvercle
US20060165711A1 (en) * 2004-12-29 2006-07-27 Bot Adrian I Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
WO2006071983A2 (fr) 2004-12-29 2006-07-06 Mannkind Corporation Combinaisons d'antigenes associes a une tumeur dans des compositions pour differents types de cancers
US20060153844A1 (en) * 2004-12-29 2006-07-13 Thomas Kundig Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
US20060159694A1 (en) * 2004-12-29 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in compositions for various types of cancers
WO2006086454A2 (fr) 2005-02-08 2006-08-17 President And Fellows Of Harvard College Procedes et compositions pour l'extension de la duree de vie et l'augmentation de la resistance au stress des cellules et des organismes
US20080254059A1 (en) * 2005-02-11 2008-10-16 Bett Andrew J Adenovirus Serotype 26 Vectors, Nucleic Acid and Viruses Produced Thereby
US20060233761A1 (en) * 2005-02-23 2006-10-19 Arnold John J Alkyl-glycoside enhanced vaccination
US7524510B2 (en) 2005-02-23 2009-04-28 The Uab Research Foundation Alkyl-glycoside enhanced vaccination
EP2325305A1 (fr) 2005-02-25 2011-05-25 Oncotherapy Science, Inc. Vaccins à base de peptides pour cancers du poumon exprimant des polypeptides TTK, URLC10 ou KOC1
EP2325306A1 (fr) 2005-02-25 2011-05-25 Oncotherapy Science, Inc. Vaccins à base de peptides pour cancers du poumon exprimant des polypeptides TTK, URLC10 ou KOC1
WO2006093030A1 (fr) 2005-02-28 2006-09-08 Oncotherapy Science, Inc. Peptides epitopes derives d’un recepteur de facteur de croissance endotheliale vasculaire 1 et vaccins contenant ces peptides
EP2289533A1 (fr) 2005-02-28 2011-03-02 Oncotherapy Science, Inc. Peptides d'épitope dérivés du récepteur 1 du facteur de croissance endothéliale vasculaire et vaccins contenant ces peptides
EP2095822A1 (fr) 2005-02-28 2009-09-02 Oncotherapy Science, Inc. Peptides d'épitope dérivés du récepteur 1 du facteur de croissance endothéliale vasculaire et vaccins contenant ces peptides
USRE45196E1 (en) 2005-03-04 2014-10-14 Dynavax Technologies Corporation Compositions comprising structurally stable conjugate molecules
US7718622B2 (en) 2005-03-04 2010-05-18 Dynavax Technologies Corporation Compositions comprising structurally stable conjugate molecules
US20070036807A1 (en) * 2005-03-04 2007-02-15 Tuck Stephen F Compositions comprising structurally stable conjugate molecules
EP2444099A1 (fr) 2005-03-31 2012-04-25 Agensys, Inc. Anticorps et molécules correspondantes se liant aux protéines 161P2F10B
EP3300739A2 (fr) 2005-03-31 2018-04-04 Agensys, Inc. Anticorps et molécules correspondantes se liant aux protéines 161p2f10b
US8674081B2 (en) 2005-06-17 2014-03-18 Mankind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
US7999088B2 (en) 2005-06-17 2011-08-16 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
WO2007013576A1 (fr) 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Gene tom34 lie au cancer du colon
US20070092517A1 (en) * 2005-08-10 2007-04-26 Oklahoma Medical Research Foundation Truncated memapsin 2 compositions and treatments
US20090214554A1 (en) * 2005-08-10 2009-08-27 Oklahoma Medical Research Foundation Truncated memapsin 2 compositions and treatments
US8900180B2 (en) 2005-11-18 2014-12-02 3M Innovative Properties Company Coatable compositions, coatings derived therefrom and microarrays having such coatings
US20080294116A1 (en) * 2005-11-18 2008-11-27 Wolter James T Coatable Compositions, Coatings Derived Therefrom and Microarrays Having Such Coatings
US20080319404A1 (en) * 2005-12-21 2008-12-25 Pekurovsky Mikhail L Microneedle Devices
EP2687540A1 (fr) 2006-10-17 2014-01-22 Oncotherapy Science, Inc. Vaccins de peptide pour cancers exprimant les polypeptides MPHOSPH1 ou DEPDC1
EP2687541A1 (fr) 2006-10-17 2014-01-22 Oncotherapy Science, Inc. Vaccins de peptide pour cancers exprimant les polypeptides MPHOSPH1 ou DEPDC1
EP2476698A2 (fr) 2006-10-17 2012-07-18 Oncotherapy Science, Inc. Vaccins de peptide pour cancers exprimant les polypeptides MPHOSPH1 ou DEPDC1
EP2476697A2 (fr) 2006-10-17 2012-07-18 Oncotherapy Science, Inc. Vaccins de peptide pour cancers exprimant les polypeptides MPHOSPH1 ou DEPDC1
EP2476699A2 (fr) 2006-10-17 2012-07-18 Oncotherapy Science, Inc. Vaccins de peptide pour cancers exprimant les polypeptides MPHOSPH1 ou DEPDC1
EP2695895A1 (fr) 2006-10-17 2014-02-12 Oncotherapy Science, Inc. Vaccins de peptide pour cancers exprimant les polypeptides MPHOSPH1 ou DEPDC1
EP2465866A2 (fr) 2007-02-21 2012-06-20 Oncotherapy Science, Inc. Vaccins de peptide pour cancers exprimant des antigènes associés aux tumeurs
EP2476695A2 (fr) 2007-02-21 2012-07-18 Oncotherapy Science, Inc. Vaccins de peptide pour cancers exprimant des antigènes associés aux tumeurs
EP2573109A2 (fr) 2007-02-21 2013-03-27 Oncotherapy Science, Inc. Vaccins de peptide avec Seq Id 101, 80 or 100 pour cancers exprimant des antigènes associés aux tumeurs
EP2465867A2 (fr) 2007-02-21 2012-06-20 Oncotherapy Science, Inc. Vaccins de peptide pour cancers exprimant des antigènes associés aux tumeurs
EP2567971A2 (fr) 2007-02-21 2013-03-13 Oncotherapy Science, Inc. Vaccins de peptides avec Seq Id 80, 100 or 101 pour cancers exprimant des antigènes associés aux tumeurs
EP2465864A2 (fr) 2007-02-21 2012-06-20 Oncotherapy Science, Inc. Vaccins de peptide pour cancers exprimant des antigènes associés aux tumeurs
EP2465865A2 (fr) 2007-02-21 2012-06-20 Oncotherapy Science, Inc. Vaccins de peptide pour cancers exprimant des antigènes associés aux tumeurs
EP2476693A2 (fr) 2007-02-21 2012-07-18 Oncotherapy Science, Inc. Vaccins de peptide pour cancers exprimant des antigènes associés aux tumeurs
EP2476694A2 (fr) 2007-02-21 2012-07-18 Oncotherapy Science, Inc. Vaccins de peptide pour cancers exprimant des antigènes associés aux tumeurs
EP2565203A1 (fr) 2007-02-21 2013-03-06 Oncotherapy Science, Inc. Vaccin de peptide avec seg id: 344 pour cancers exprimant des antigènes associés aux tumeurs
WO2008102557A1 (fr) 2007-02-21 2008-08-28 Oncotherapy Science, Inc. Vaccins peptidiques pour les cancers exprimant des antigènes associés à une tumeur
EP2476692A2 (fr) 2007-02-21 2012-07-18 Oncotherapy Science, Inc. Vaccins de peptide pour cancers exprimant des antigènes associés aux tumeurs
WO2008109953A1 (fr) * 2007-03-14 2008-09-18 Sai Ying Ko Procédé de traitement du cancer par l'administration mucosale d'interleukine
EP2508601A2 (fr) 2007-04-11 2012-10-10 Oncotherapy Science, Inc. Peptides Tem8 et vaccins les comportant
WO2008126413A1 (fr) 2007-04-11 2008-10-23 Oncotherapy Science, Inc. Peptides tem8 et vaccins les comprenant
WO2009059011A2 (fr) 2007-11-01 2009-05-07 Mayo Foundation For Medical Education And Research Peptides de liaison hla-dr et leurs utilisations
EP2612868A1 (fr) 2007-11-01 2013-07-10 Perseid Therapeutics LLC Acides nucléiques et polypeptides immunosuppresseurs
EP2612867A1 (fr) 2007-11-01 2013-07-10 Perseid Therapeutics LLC Acides nucléiques et polypeptides immunosuppresseurs
US10556943B2 (en) 2007-11-01 2020-02-11 Mayo Foundation For Medical Education And Research HLA-DR binding peptides and their uses
WO2009058564A2 (fr) 2007-11-01 2009-05-07 Maxygen, Inc. Polypeptide immunosuppresseur et acides nucléiques
EP3085707A1 (fr) 2007-11-01 2016-10-26 Mayo Foundation for Medical Education and Research Peptides de liaison hla-dr et leurs utilisations
EP2385065A1 (fr) 2007-11-01 2011-11-09 Perseid Therapeutics LLC Polypeptides immunosuppresseurs et acides nucléiques
US20100310640A1 (en) * 2007-11-01 2010-12-09 Knutson Keith L Hla-dr binding peptides and their uses
US7928189B2 (en) 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
US20090275504A1 (en) * 2008-05-05 2009-11-05 Janice Mayne Pcsk9 proteins, fragments thereof and methods of modulating pcsk9 phosphorylation and low density lipoprotein (ldlr) degradation
US9644212B2 (en) 2008-05-19 2017-05-09 Advaxis, Inc. Dual delivery system for heterologous antigens
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
WO2010023877A1 (fr) 2008-08-27 2010-03-04 Oncotherapy Science, Inc. Prmt1 pour gènes cibles du traitement et du diagnostic du cancer
US8784829B2 (en) 2008-10-23 2014-07-22 Intervet Inc. Lawsonia intracellularis vaccines
US20110200631A1 (en) * 2008-10-23 2011-08-18 Morsey Mohamad A Lawsonia intracellularis vaccines
US9416371B2 (en) 2008-10-31 2016-08-16 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
EP3115063A2 (fr) 2008-12-03 2017-01-11 The John Hopkins University Galectin-3 et annexin a2 comme cible immunologique
WO2010065613A2 (fr) 2008-12-03 2010-06-10 The Johns Hopkins University Annexina2 en tant que cible immunologique
EP3219720A2 (fr) 2008-12-05 2017-09-20 Onco Therapy Science, Inc. Peptides à épitope wdrpuh et vaccins les contenant
EP4047009A2 (fr) 2008-12-05 2022-08-24 OncoTherapy Science, Inc. Peptides à épitope wdrpuh et vaccins les contenant
WO2010080985A1 (fr) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions et procédés pour induire la différenciation du tissu adipeux brun
WO2010083203A2 (fr) 2009-01-13 2010-07-22 StemBios Technologies, Inc. Cellules souches non embryonnaires et leurs utilisations
WO2010086294A2 (fr) 2009-01-28 2010-08-05 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations
US20100305197A1 (en) * 2009-02-05 2010-12-02 Massachusetts Institute Of Technology Conditionally Active Ribozymes And Uses Thereof
WO2010095428A1 (fr) 2009-02-18 2010-08-26 Oncotherapy Science, Inc. Peptides foxm1 et vaccins contenant ceux-ci
WO2010106770A1 (fr) 2009-03-18 2010-09-23 Oncotherapy Science, Inc. Peptides neil3 et vaccins les comprenant
WO2010124365A1 (fr) 2009-04-27 2010-11-04 Ottawa Hospital Research Institute Compositions et méthodes permettant de moduler les cellules souches et leurs utilisations
US10071138B2 (en) 2009-04-27 2018-09-11 Ottawa Hospital Research Institute Compositions and methods for modulating stem cells and uses thereof
US10828346B2 (en) 2009-04-27 2020-11-10 Ottawa Hospital Research Institute Compositions and methods for modulating stem cells and uses thereof
EP3556857A2 (fr) 2009-05-26 2019-10-23 Oncotherapy Science, Inc. Peptides cdc45l et vaccins les comportant
WO2010137295A1 (fr) 2009-05-26 2010-12-02 Oncotherapy Science, Inc. Peptides cdc45l et vaccins comprenant ceux-ci
EP3208334A2 (fr) 2009-05-26 2017-08-23 Oncotherapy Science, Inc. Peptides cdc45l et vaccins les comportant
EP3868778A2 (fr) 2009-05-26 2021-08-25 OncoTherapy Science, Inc. Peptides cdc45l et vaccins les comportant
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
WO2011074236A1 (fr) 2009-12-14 2011-06-23 Oncotherapy Science, Inc. Peptides tmem22 et vaccins les comprenant
WO2011106705A2 (fr) 2010-02-26 2011-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Protocoles de vaccination adn/protéine
WO2011111392A1 (fr) 2010-03-11 2011-09-15 Oncotherapy Science, Inc. Peptides hjurp et vaccins les comprenant
WO2011122022A1 (fr) 2010-04-02 2011-10-06 Oncotherapy Science, Inc. Peptides d'ect2 et vaccins les comprenant
EP3569696A1 (fr) 2010-08-04 2019-11-20 Stembios Technologies, Inc. Cellules souches somatiques
WO2012019002A2 (fr) 2010-08-04 2012-02-09 StemBios Technologies, Inc. Cellules souches somatiques
WO2012041867A2 (fr) 2010-09-27 2012-04-05 China Agricultural University Vaccin polyvalent comprenant un antigène et un adn destiné à prévenir et à traiter des maladies autoimmunes
US9943590B2 (en) 2010-10-01 2018-04-17 The Trustees Of The University Of Pennsylvania Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
US11633606B2 (en) 2010-11-08 2023-04-25 The Johns Hopkins University Methods for improving heart function
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
WO2012068463A2 (fr) 2010-11-18 2012-05-24 Beth Israel Deaconess Medicall Center, Inc. Méthodes de traitement de l'obésité par inhibition de la nicotinamide n-méthyltransférase (nnmt)
WO2012071513A2 (fr) 2010-11-24 2012-05-31 Hong Gao Expansion de cellules souches hématopoïétiques
EP3026432A2 (fr) 2010-12-27 2016-06-01 Brown University Procédé de prévision de la réponse du patient au traitement avec biglycan
US9463227B2 (en) 2011-03-11 2016-10-11 Advaxis, Inc. Listeria-based adjuvants
US10064898B2 (en) 2011-03-11 2018-09-04 Advaxis, Inc. Listeria-based adjuvants
US9605275B2 (en) 2011-03-21 2017-03-28 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
US11141477B2 (en) 2011-03-21 2021-10-12 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
US9175310B2 (en) 2011-03-21 2015-11-03 Altimmune Inc Rapid and prolonged immunologic-therapeutic
US11040100B2 (en) 2011-03-21 2021-06-22 Altimmune Inc. Rapid and prolonged immunogic therapeutic
US11040099B2 (en) 2011-03-21 2021-06-22 Altimmune, Inc. Rapid and prolonged immunologic therapeutic
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
WO2013018690A1 (fr) 2011-07-29 2013-02-07 国立大学法人徳島大学 Peptide issu de erap1 et son utilisation
WO2013024582A1 (fr) 2011-08-12 2013-02-21 Oncotherapy Science, Inc. Peptides mphosph1 et vaccins les contenant
WO2013039996A1 (fr) 2011-09-13 2013-03-21 Dana-Farber Cancer Institute, Inc. Compositions et procédés pour induction et activité de tissu adipeux brun à l'aide de fndc5
WO2013040341A2 (fr) 2011-09-16 2013-03-21 Ottawa Hospital Research Institute Compositions wnt7a et leurs procédés d'utilisation
US9732130B2 (en) 2011-09-16 2017-08-15 Ottawa Hospital Research Institute WNT7A compositions and method of using the same
US9873722B2 (en) 2011-09-16 2018-01-23 Fate Therapeutics, Inc. Wnt compositions and therapeutic uses of such compositions
WO2013049459A2 (fr) 2011-09-28 2013-04-04 StemBios Technologies, Inc. Cellules souches somatiques
EP3406711A1 (fr) 2011-09-28 2018-11-28 Stembios Technologies, Inc. Cellules souches somatiques
WO2013055911A1 (fr) 2011-10-14 2013-04-18 Dana-Farber Cancer Institute, Inc. Biomarqueur znf365/zfp365 pouvant prévoir une réponse anticancéreuse
EP3296317A1 (fr) 2011-10-28 2018-03-21 OncoTherapy Science, Inc. Peptides topk et vaccins les comportant
WO2013116965A1 (fr) 2012-02-10 2013-08-15 Beijing Advaccine Biotechnology Co. Ltd Vaccin associant un antigène et un adn pour la prévention et le traitement d'une infection par un vrs
US10058599B2 (en) 2012-03-12 2018-08-28 Advaxis, Inc. Suppressor cell function inhibition following Listeria vaccine treatment
WO2014010232A1 (fr) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Peptides épitopes du ly6k pour cellules th1 et vaccins les contenant
WO2014010231A1 (fr) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Peptides épitopes du kif20a pour cellules th1 et vaccins les contenant
WO2014041784A1 (fr) 2012-09-11 2014-03-20 Oncotherapy Science, Inc. Peptides ube2t et vaccins les contenant
WO2014044690A1 (fr) 2012-09-18 2014-03-27 Valneva Austria Gmbh Vaccins améliorés
EP3782640A1 (fr) 2012-12-13 2021-02-24 The Trustees Of The University Of Pennsylvania Vaccin wt1
WO2014093897A1 (fr) 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Vaccin contre wt1
WO2014141683A1 (fr) 2013-03-12 2014-09-18 Oncotherapy Science, Inc. Peptides kntc2 et vaccins les contenant
EP3421047A1 (fr) 2013-03-27 2019-01-02 ImmunoVaccine Technologies Inc. Procédé d'amélioration de l'efficacité d'un vaccin à base de survivine pour le traitement du cancer
US10022441B2 (en) 2013-03-27 2018-07-17 Immunovaccine Technologies, Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
US10729766B2 (en) 2013-03-27 2020-08-04 Immunovaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
US9592303B2 (en) 2013-05-30 2017-03-14 Duke University Enzyme-catalyzed synthesis of site-specific and stoichiometric biomolecule-polymer conjugates
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
EP2816107A1 (fr) 2013-06-17 2014-12-24 Hong Gao Procédé d'expansion de cellules souches hématopoïétiques
WO2015054012A1 (fr) 2013-10-07 2015-04-16 The Trustees Of The University Of Pennsylvania Vaccins ayant pour adjuvant l'interleukine-33
US10370664B2 (en) 2013-11-07 2019-08-06 University Of Southern California Use of IKK epsilon inhibitors to activate NFAT and T cell response
EP3964231A1 (fr) 2013-11-14 2022-03-09 Inovio Pharmaceuticals, Inc. Vaccin adn env plus rappel avec protéine contre le vih-1
WO2015081155A1 (fr) 2013-11-29 2015-06-04 The Trustees Of The University Of Pennsylvania Vaccin à base de mers-cov
EP4070818A2 (fr) 2014-01-06 2022-10-12 The Trustees of the University of Pennsylvania Anticorps pd1 et pdl1 et combinaisons de vaccin et leur utilisation pour l'immunothérapie
WO2015164743A2 (fr) 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Suppresseur de tumeur et biomarqueurs oncogènes prédictifs de réponse à un inhibiteur de point de contrôle anti-immunitaire
EP4353321A2 (fr) 2014-08-04 2024-04-17 OncoTherapy Science, Inc. Peptide dérivé de koc1 et vaccin le comprenant
EP4282883A2 (fr) 2014-08-04 2023-11-29 OncoTherapy Science, Inc. Peptide dérivé de cdca1 et vaccin le contenant
EP3848383A2 (fr) 2014-08-04 2021-07-14 Oncotherapy Science, Inc. Peptide dérivé d'urlc10 et vaccin le contenant
EP3981416A2 (fr) 2014-08-04 2022-04-13 OncoTherapy Science, Inc. Peptide dérivé de koc1 et vaccin le comportant
WO2016054003A1 (fr) 2014-10-01 2016-04-07 The Trustees Of The University Of Pennsylvania Vaccins possédant un antigène et une interleukine-21 en tant qu'adjuvant
WO2016057367A1 (fr) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Biomarqueurs à base d'angiopoïétine -2 utilisés pour la prédiction de la réponse de point de contrôle anti-immunitaire
WO2016057651A1 (fr) 2014-10-09 2016-04-14 Dana-Farber Cancer Institute, Inc. Schéma posologique d'il-2 variables multiples pour le traitement de troubles immunitaires
US11439709B2 (en) 2014-11-17 2022-09-13 Cellectar Biosciences, Inc. Phospholipid ether analogs as cancer-targeting drug vehicles
US10988500B2 (en) 2015-01-06 2021-04-27 Immunovaccine Technologies Inc. Lipid A mimics, methods of preparation, and uses thereof
US10533033B2 (en) 2015-01-06 2020-01-14 Immunovaccine Technologies Inc. Lipid A mimics, methods of preparation, and uses thereof
WO2016123285A1 (fr) 2015-01-29 2016-08-04 The Trustees Of The University Of Pennsylvania Associations d'inhibiteurs de point de contrôle immunitaires et de vaccins, et leur utilisation en immunothérapie
WO2016144673A1 (fr) 2015-03-06 2016-09-15 Dana-Farber Cancer Institute, Inc. Biomarqueurs pd-l2 prédictifs de réponses d'inhibiteurs de la voie pd-1 dans les cancers oesophagogastriques
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
WO2016183420A1 (fr) 2015-05-13 2016-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Procédés et compositions pour induire une réponse immunitaire à l'aide de constructions d'éléments conservés
EP4276106A2 (fr) 2015-05-13 2023-11-15 The United States of America as represented by the Secretary of the Department of Health and Human Services Methodes et compositions pour eliciter des reponses immune a base des constructs contenant des elements conservatives
US11458205B2 (en) 2015-08-04 2022-10-04 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
WO2017024182A1 (fr) 2015-08-04 2017-02-09 Duke University Polymères discrets intrinsèquement désordonnés codés génétiquement pour administration et leurs procédés d'utilisation
EP4219525A2 (fr) 2015-10-08 2023-08-02 OncoTherapy Science, Inc. Peptide dérivé de foxm1 et vaccin le contenant
WO2017066561A2 (fr) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Modulation de pd-1 des lymphocytes t régulateurs pour réguler les réponses immunitaires effectrices des lymphocytes t
WO2017075329A2 (fr) 2015-10-29 2017-05-04 Dana-Farber Cancer Institute, Inc. Procédés pour identifier, évaluer, prévenir et traiter des troubles métaboliques au moyen de pm20d1 et d'acides aminés n-lipidés
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
WO2017112825A2 (fr) 2015-12-21 2017-06-29 Duke University Conjugués polymères ayant une antigénicité réduite et leurs procédés d'utilisation
WO2017165412A2 (fr) 2016-03-21 2017-09-28 Dana-Farber Cancer Institute, Inc. Régulateurs de l'expression génique spécifiques à l'état d'épuisement des lymphocytes t et leurs utilisations
US11246924B2 (en) 2016-04-01 2022-02-15 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
WO2017190147A1 (fr) 2016-04-29 2017-11-02 Inovio Pharmaceuticals, Inc. Utilisation in vivo de chondroïtinase et/ou d'hyaluronidase pour améliorer l'administration d'un agent
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
US11135301B2 (en) 2016-09-14 2021-10-05 Duke University Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
WO2018057618A1 (fr) 2016-09-20 2018-03-29 Dana-Farber Cancer Institute, Inc. Compositions et méthodes pour l'identification, l'évaluation, la prévention et le traitement de la lma au moyen de biomarqueurs usp10 et de modulateurs
US12084480B2 (en) 2016-09-23 2024-09-10 Duke University Unstructured non-repetitive polypeptides having lcst behavior
US11155584B2 (en) 2016-09-23 2021-10-26 Duke University Unstructured non-repetitive polypeptides having LCST behavior
WO2018094106A2 (fr) 2016-11-16 2018-05-24 University Of South Florida Antagonistes allostériques de gprc6a et leur utilisation dans l'atténuation de protéinopathies
US10376495B2 (en) 2016-11-23 2019-08-13 University Of South Florida Small molecules that mimic or antagonize actions of granulocyte colony-stimulating-factor (G-CSF)
US10813913B2 (en) 2016-11-23 2020-10-27 University Of South Florida Small molecules that mimic or antagonize actions of granulocyte colony-stimulating-factor (G-CSF)
WO2018129040A1 (fr) 2017-01-04 2018-07-12 President And Fellows Of Harvard College Modulation du domaine d'homologie nudix (nhd) avec des analogues mononucléotidiques de nicotinamide et leurs dérivés
WO2018129039A1 (fr) 2017-01-04 2018-07-12 President And Fellows Of Harvard College Modulation du domaine d'homologie nudix (nhd) au moyen d'analogues de mononucléotide de nicotinamide et leurs dérivés
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
US10813935B2 (en) 2017-02-23 2020-10-27 Transgenex Nanobiotech, Inc. Methods and compositions for treating drug resistance in cancer
US10272052B2 (en) 2017-02-24 2019-04-30 University Of South Florida Compositions and methods for the treatment of tauopathies
US10653642B2 (en) 2017-02-24 2020-05-19 University Of South Florida Compositions and methods for the treatment of tauopathies
US11931373B2 (en) 2017-02-24 2024-03-19 University Of South Florida HSP90 activator AHA1 drives production of pathological tau aggregates
US11318155B2 (en) 2017-02-24 2022-05-03 University Of South Florida Hsp90 activator Aha1 drives production of pathological tau aggregates
US10675283B2 (en) 2017-03-24 2020-06-09 University Of South Florida Compositions and methods for white to beige adipogenesis
US10828304B2 (en) 2017-03-24 2020-11-10 University Of South Florida Compositions and methods for white to beige adipogenesis
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
US11820822B2 (en) 2017-06-06 2023-11-21 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
US11980671B2 (en) 2017-07-26 2024-05-14 Duke University Use of bacterial voltage gated ion channels for human therapies
US12098172B2 (en) 2017-07-31 2024-09-24 The Johns Hopkins University Compositions and methods for targeting MASAs to treat cancers with spliceosome mutations
US11629127B2 (en) 2017-10-25 2023-04-18 University Of South Florida Drug-induced activation of the Reelin signaling system
US11306059B2 (en) 2017-10-25 2022-04-19 University Of South Florida Drug-induced activation of the Reelin signaling system
US12018255B2 (en) 2017-12-08 2024-06-25 University Of Connecticut Compositions and methods for treating disorders of genomic imprinting
US10538553B2 (en) 2018-01-05 2020-01-21 University Of South Florida Compounds for the treatment of neurodegenerative diseases
US10836793B2 (en) 2018-01-05 2020-11-17 University Of South Florida Compounds for the treatment of neurodegenerative diseases
US11254704B2 (en) 2018-01-05 2022-02-22 University Of South Florida Compounds and methods for reducing or inhibiting aggregation of proteins in a subject
WO2019144047A1 (fr) 2018-01-18 2019-07-25 University Of South Florida Cellules dendritiques hétérogènes immatures mortes stimulées par un antigène en tant qu'agents thérapeutiques de maladies
US11491206B1 (en) 2018-02-13 2022-11-08 Duke University Compositions and methods for the treatment of trail-resistant cancer
WO2019165372A1 (fr) 2018-02-26 2019-08-29 President And Fellows Of Harvard College Compositions de modulateurs et/ou de mutants de parp14 et leur utilisation thérapeutique
WO2019199673A1 (fr) 2018-04-09 2019-10-17 President And Fellows Of Harvard College Modulateurs de récepteurs nucléaires et leurs procédés d'utilisation
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
WO2020027239A1 (fr) 2018-08-02 2020-02-06 オンコセラピー・サイエンス株式会社 Peptide dérivé de cdca1 et vaccin le contenant
WO2020111167A1 (fr) 2018-11-30 2020-06-04 国立大学法人徳島大学 Agent thérapeutique pour le traitement du cancer du sein comprenant un peptide inhibiteur d'interaction big3-phb2 dérivé de phb2
WO2020223121A1 (fr) 2019-04-30 2020-11-05 Dana-Farber Cancer Institute, Inc. Méthodes de traitement du cancer à l'aide de combinaisons d'agents anti-cx3cr1 et d'agents de blocage de points de contrôle immunitaires
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
US11965164B2 (en) 2019-07-12 2024-04-23 Duke University Amphiphilic polynucleotides
WO2021072300A1 (fr) 2019-10-10 2021-04-15 Cellectar Biosciences, Inc. Conjugués phospholipide-flavagline et procédés d'utilisation de ceux-ci pour une thérapie anticancéreuse ciblée
US10751360B1 (en) 2019-10-23 2020-08-25 Korea Institute Of Science And Technology Pharmaceutical composition for the prevention or treatment of nicotine addiction and withdrawal symptoms including miRNA
US10946037B1 (en) 2019-10-23 2021-03-16 Korea Institute Of Science And Technology Pharmaceutical composition for the prevention or treatment of nicotine addiction and withdrawal symptoms including miRNA
US11660335B2 (en) 2020-02-25 2023-05-30 Inovio Pharmaceuticals, Inc. Vaccines against coronavirus and methods of use
WO2021173829A1 (fr) 2020-02-25 2021-09-02 Inovio Pharmaceuticals, Inc. Vaccins contre le coronavirus et leurs méthodes d'utilisation
US11744885B2 (en) 2020-05-14 2023-09-05 Inovio Pharmaceuticals, Inc. Vaccines for recurrent respiratory papillomatosis and methods of using the same
WO2021252354A1 (fr) 2020-06-12 2021-12-16 University Of Rochester Codage et expression d'arnt ace
WO2022086852A2 (fr) 2020-10-19 2022-04-28 Dana-Farber Cancer Institute, Inc. Biomarqueurs germinaux de la réponse clinique et du bénéfice d'un traitement par inhibiteur de points de contrôle immunitaire
EP4343004A2 (fr) 2020-10-19 2024-03-27 Dana-Farber Cancer Institute, Inc. Biomarqueurs germinaux de réponse clinique et de bénéfice d'une thérapie par inhibiteur de point de contrôle immunitaire
WO2022104104A2 (fr) 2020-11-13 2022-05-19 Dana-Farber Cancer Institute, Inc. Vaccins à cellules de fusion personnalisés
WO2022159793A2 (fr) 2021-01-25 2022-07-28 Dana-Farber Cancer Institute, Inc. Procédés et compositions pour identifier un cancer de la prostate neuroendocrinien
WO2022178438A1 (fr) 2021-02-22 2022-08-25 Duke University Conjugués poegma-aptamères non immunogènes
WO2022261183A2 (fr) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions et procédés de traitement et/ou d'identification d'un agent pour le traitement de cancers intestinaux
WO2023004332A2 (fr) 2021-07-19 2023-01-26 New York University Compositions de vecteurs viraux adéno-associés et méthodes de promotion de la régénération musculaire
WO2023097119A2 (fr) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Méthodes et compositions pour moduler riok2
WO2023150753A1 (fr) 2022-02-07 2023-08-10 University Of Rochester Séquences optimisées pour une expression d'adn améliorée et/ou une suppression de mutation non sens
WO2023158732A1 (fr) 2022-02-16 2023-08-24 Dana-Farber Cancer Institute, Inc. Procédés de diminution de l'alpha-synucléine pathologique à l'aide d'agents qui modulent fndc5 ou des fragments biologiquement actifs de celui-ci
WO2024011033A1 (fr) 2022-07-07 2024-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogènes et procédés pour induire une réponse immunitaire
WO2024102187A1 (fr) 2022-11-07 2024-05-16 Pinetree Therapeutics, Inc. Polythérapie comprenant des anticorps bispécifiques comprenant un domaine de liaison nrp1
WO2024129459A1 (fr) 2022-12-16 2024-06-20 University Of Rochester Réparation d'un dysfonctionnement de la barrière dans l'œsophage
WO2024178172A1 (fr) 2023-02-23 2024-08-29 University Of Rochester Agents et méthodes de production de molécules de fil d'adn à extrémités fermées

Also Published As

Publication number Publication date
EP0789574B1 (fr) 2006-04-19
JPH10509702A (ja) 1998-09-22
CA2203991C (fr) 2002-08-20
AU4198196A (en) 1996-05-31
DE69534946D1 (de) 2006-05-24
ATE323496T1 (de) 2006-05-15
EP0789574A1 (fr) 1997-08-20
CA2203991A1 (fr) 1996-05-17
DE69534946T2 (de) 2006-12-28
EP0789574A4 (fr) 2001-08-29
WO1996014074A1 (fr) 1996-05-17

Similar Documents

Publication Publication Date Title
US5679647A (en) Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
CA2204253C (fr) Procedes et equipements d'immunisation d'un hote par administration de polynucleotides nus codant pour des peptides antigenes
US5985847A (en) Devices for administration of naked polynucleotides which encode biologically active peptides
CA2244946C (fr) Vecteurs d'expression genique generant une reponse immune specifique d'un antigene et leurs procedes d'utilisation
CA2169635C (fr) Methode, compositions et dispositifs pour administrer des polynucleotides nus codant des peptides biologiquement actifs
US6951845B2 (en) Method for treating allergic lung disease
US6110898A (en) DNA vaccines for eliciting a mucosal immune response
US9078843B2 (en) Immunogenic fragments of T-cell receptor constant domains and peptides derived therefrom
US20030186921A1 (en) Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
JPH08508252A (ja) 小胞体シグナル配列ペプチドと少なくとも１個の他のペプチドをエンコードする核酸配列を含有する免疫原性キメラ、及びこのキメラのワクチン及び疾患の治療における使用
US20050025754A1 (en) Increased T-cell tumor infiltration by mutant light
AU2011201813A1 (en) Poxvirus vector encoding prostate specific antigens for treatment of prostate cancer
JP2002528466A (ja) 哺乳類治療用の医薬組成物調製のための生物材料
AU759590B2 (en) Gene expression vectors which generate an antigen specific immune response and methods of using the same
AU1841897A (en) Gene expression vectors which generate an antigen specific immune response and methods of using the same
Virus-Specific Adenovirus-Transduced Dendritic Cells

Legal Events

Date Code Title Description
AS Assignment

Owner name: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE, CALI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CARSON, DENNIS A.;RAZ, EYAL;REEL/FRAME:007442/0835

Effective date: 19950111

CC Certificate of correction
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 4

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20091021